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SUMMARY
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Breast cancer is the leading cause of death in women worldwide and these deaths
are mostly attributed to metastasis and tumour recurrence following initially successful
therapy. Metastasis refers to the development of invasive disease, wherein malignant
cells dissociate from primary tumours, infiltrating other organs and tissues to give rise
to secondary outgrowths. Previously, metastasis was thought to be initiated in advanced
tumours, but breast cancer cellsh with metastatic potential have now been shown to
disseminate very early from the primary site via largely unknown mechanisms. These early
interactions of tumour cells with their cellular micro-environment and normal neighbours
also results in early tumour cell heterogeneity and must therefore be elucidated such that
we can prevent metastatic spread in the patient situation and better treat the resulting
heterogenous tumours. However, studying tumour initiation is not possible in patients
because it happens on a cellular level not detectable by current technology. Tumour
recurrence is another major cause of breast cancer related death and is believed to be
caused by residual disease cells that survive initial therapy. These are a reservoir of
refractory cells that can lay dormant for many years (sometimes decades) before resulting
in relapse tumours. They are also difficult to obtain from human patients, since they are
very few and cannot be detected easily, and thus their molecular mechanisms have not
been fully explored.
In addition to the unavailability of human tissue, mouse models of breast cancer also fall
short in helping us study early cancer initiation, because they allow oncogenic expression in
all cells of the tissue instead of initiating cancer like in the human situation—one neoplastic
transformed cell proliferating unchecked in a normal epithelium. To address this issue, we
used primary organoids from an inducible mouse model of breast cancer and lentivirally
transduced single cells within these organoids to express oncogenes. We further optimized
parameters for long term imaging using light sheet microscopy and developed big data
analysis pipelines that lead us to discern that single transformed cells had a lower chance
at establishing tumorigenic foci, when compared to clusters of cells. Thus, we postulate
a proximity-controlled signalling that is imperative to tumour initiation within epithelial
tissues using the first ever in vitro stochastic breast tumorigenesis model system. This new
stochastic tumorigenesis system can be further used to identify the molecular interactions
in the early breast cancer cells.
Our group has already revealed distinct characteristics, such as dysregulated lipid
metabolism, of the residual disease correlate obtained from an inducible mouse model.
As survival mechanisms invoked by residual cells remain largely unknown, we analysed
the dynamic transcriptome of regressing tumours at important timepoints during the
establishment of residual disease. Key molecular players upregulated during regression –
like c-Jun and BCL6 – were identified and the inflammatory arm of the Nf-kB cascade was
found to be dysregulated among others. Further validation of these molecular targets as
potentially synthetic lethal interactors remains to be performed so that they can be used
to limit the residual disease reservoir and eventually tumour recurrence.
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ZUSAMMENFASSUNG
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Brustkrebs ist die häufigste Todesursache bei Frauen weltweit. Die auftretenden
Todesfälle sind dabei hauptsächlich auf Metastasen und Brustkrebs im Rezidiv nach
anfänglich erfolgreicher Therapie zurückzuführen. Unter Metastasen versteht man Tu-
morzellen die den Zellverbund des Primärtumors verlassen haben, und sich in weit ent-
fernten Organen sowie Geweben des Körpers neu anzusiedeln. Lange wurde angenom-
men, dass besonders fortgeschrittene Tumore Metastasen bilden. Heute weiß man, dass
sich Brustkrebszellen bereits frühzeitig und noch auf ungeklärte Weise vom Primärtumor
lösen können. Die somit schon frühen Interaktionen von Krebszellen mit ihrer Umgebung
sowie gesunden Nachbarzellen führen zu heterogenen Tumoren. Diese gilt es eingehend
zu erforschen um Metastasen und daraus resultierende heterogene Tumore in Brustkreb-
spatienten besser behandeln zu können. Die frühzeitige Erkennung der Brustkrebsbildung
ist in Patienten derzeit unmöglich, da sich anfangs nur wenige Tumorzellen bilden, welche
zudem mit heutigen Techniken nicht zu identifizieren sind. Eine weitere Ursache für den
Tod von Brustkrebspatienten ist das erneute ausbrechen bereits erfolgreich behandelter
Tumore, sogenannte Rezidive. Rezidive sind auf wenige widerstandsfähige Tumorzellen
zurückzuführen, welche während einer ersten Behandlung nicht vollständig abgestorben
sind. Diese Zellen können in inaktivem Zustand über Jahre im Körper des Patienten
überdauern und auch noch nach Jahrzenten einen weiteren Brustkrebs hervorrufen. Bisher
sind solch inaktive Tumorzellen unmöglich aus bereits behandelten Patienten zu isolieren,
da sie in geringer Zahl vorliegen und mit heutigen Techniken nicht zu identifiziert sind.
Aus diesem Grund sind molekulare Grundlagen für Rezidive unzureichend erforscht.
Um Rezidive besser zu erforschen sind neben der Unverfügbarkeit menschlicher Tu-
morproben auch Brustkrebsmodelle aus Mäusen wenig Hilfreich. In Mausmodellen lassen
sich Tumore derzeit nur in allen Zellen eines Gewebes auslösen. Mein Ziel hingegen ist,
Brustkrebs durch nur eine Krebszelle in einem sonst gesunden Gewebe hervorzurufen,
ähnlich wie es bei Brustkrebspatienten der Fall ist. Daher verwende ich primäre Organoide
welche aus induzierbaren Brustkrebs Mausmodellen gewonnen wurden. Dabei wird eine
einzelne Zelle dieses Organoids durch einen Lentivirus infiziert, wodurch entsprechende
Krebs Gene aktiviert werden. Zudem habe ich die nötigen Parameter zur Langzeit-
bildgebung mittels Light Sheet Mikroskopie“ optimiert. Die zusätzliche Entwicklung
von big data analysis pipelines“ erlaubte mir herauszufinden, dass einzelne Krebszellen
weniger wahrscheinlich zu Tumorherden beitragen als ganze Gruppen von Krebszellen.
Durch die erstmalige Verwendung eines stochastischen in-vitro Brustkrebsmodells kon-
nte ich zeigen, dass eine Umgebungskontrollierte Signalübertragung unabdingbar ist um
Brustkrebs hervorzurufen. Dieses neuartig stochastische Brustkrebsmodell kann zudem
zur Identifizierung von makromolekularen Interaktionen in noch frühen Brustkrebszellen
verwendet werden.
Durch induzierbare Brustkrebsmodelle in der Maus konnte unser Labor bereits charak-
teristische Eigenschaften von Rezidiven identifizieren. Eine Haupteigenschaft war dabei
ein dysregulierter Lipid Metabolismus. Da Überlebensmechanismen von inaktiven aber
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jederzeit rückfälligen Tumorzellen unbekannt sind, haben wir zu verschiedenen Zeitpunk-
ten das Transkriptom jener Brustkrebszellen analysiert, die auf dem Weg der Inaktivierung
waren. Dabei hat sich herausgestellt, dass Schlüsselproteine wie c-Jun und BCL6 während
der Tumorregression vermehrt exprimiert wurden. Zudem war der inflammatorische Sig-
nalweg der Nf-kB Kaskade neben anderen Signalwegen dysreguliert. Die Validierung dieser
Molekularen Targets als potentiell synthetisch letale Interaktoren steht noch aus. Sobald
diese durchgeführt wurden, werden identifizierte Targets möglicherweise dazu beitragen
inaktive Tumorzellen zu behandeln und ein erneutes Auftreten des Brustkrebses zu ver-
hindern.
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Introduction
1.1 Breast Cancer
Breast anatomy
Breasts, medically known as the mammary glands, are composed of two compartments -
glandular and stromal. The stromal compartment of the mammary gland consists of the
fat tissue and connective tissue that surrounds the glandular compartment. The glandular
compartment, in turn, is made up of lobules and ducts. Lobules are milk-producing struc-
tures, and a system of ducts transports milk from the lobules to the nipple. Blood vessels
along with the lymph nodes, immune cells and nerve endings are located throughout the
breast (Figure 1.1) [1].
Chest wall
Pectoralis muscles
Lobe
Nipple
Areola
Milk Ducts
Fat tissue
TDLU 
(Terminal Ductal 
Lobular Unit)
Lobular Acinus
Lobe
Intralobular 
duct
Extralobular 
duct
Luminal epithelial cells
Myoepithelial cells
Basement Membrane
Figure 1.1: Human breast anatomy showing the glandular and stromal cell compartments
of the mammary tissue. The functional unit of the mammary tissue is the TDLU that
is composed of hundreds of acini- each of which consist of a double epithelial cell layer
enclosing the lumen. Figure modified from [2]
Each breast has 12 to 20 sections, or lobes, that surround the nipple in a radial manner,
like spokes on a wheel. The lobes are composed of lobules, the structural and functional
units of the mammary gland also called terminal ductal lobular units (TLDUs) [3] [4].
The innermost layer of a TDLU is formed of polarized luminal epithelial cells. The lu-
men formed by these cells is where milk is secreted during lactation (in the lobules) and
transported (in the ducts). The second layer of cells surrounding this lumen consists of
myoepithelial (basal) cells [5]. These are divided from the surrounding stroma by a base-
14
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ment membrane, which serves as an important barrier and dynamic structure composed
of extra-cellular matrix proteins [6]. Breast cancer arises mostly from abnormal epithelial
cells contained within the glandular epithelial compartment of the breast.
Breast carcinoma
Transformed epithelial cells in the breast proliferate and start to fill the lumen in the
earlier stages of carcinoma known as the non-invasive stage. Ductal carcinoma in situ
(DCIS) is confined to the milk ducts. It is the most common form of non-invasive breast
cancer accounting for up to 80% of clinical cases. Lobular carcinoma in situ (LCIS) is
confined to the milk-producing glands (Figure 1.2). Unlike DCIS, LCIS is not known to
be a pre-malignant condition, but rather a marker that identifies women at an increased
risk for invasive breast cancer [7]. As the disease progresses to invasive and metastatic
cancer, cells breach the basement membrane and grow into the surrounding normal tissue
and eventually home in distant organs [8].
Figure 1.2: Ductal carcinoma (left panel) involves abnormal cell proliferation in the mam-
mary gland ducts, while in lobular carcinoma outgrowths are seen in the lobules (right
panel). When the transformed cells are confined to the duct/lobule it is called carcinoma
in situ. Invasion of surrounding tissue by cancer cells in both cases is seen in metastatic
disease. Figure modified from [9].
Breast carcinoma is the leading cause of death among women in most developed coun-
tries[10]. Last year, over 2 million new cases of breast cancer were reported in the world
15
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and over 620,000 women succumbed to this disease and died [11]. For decades, we have
been trying to limit and eradicate this disease and yet the fatalities continue to persist.
This has, primarily, to do with the fact that cancer, irrespective of it’s tissue of origin, is a
complex collection of diseases which exhibit in biologically different entities and governed
by intrinsic cell properties and system factors. Thus, it can have distinct clinical implica-
tions on an individual patient basis [12] [13] [14].
Molecular classification of Breast Cancer
Traditional clinico-pathological variables have been conventionally used for patient prog-
nosis and management. These include factors like tumor size, tumor grade and nodal
involvement, invasive behaviour and some standard immunohistochemistry (IHC) mark-
ers for hormone receptors [15] [16]. Our advances in the genetic profiling of tumors have
proven that response to treatment is actually not determined by anatomical prognostic
factors but rather by intrinsic molecular characteristics that can be defined by gene ex-
pression patterns of specific tumors [17][18].
As such, gene expression signatures are now commonly used to classify breast cancers
[12] in five intrinsic sub-types with distinct clinical outcomes:
• Luminal A
• Luminal B
• HER2 over-expressed
• Basal
• Normal-like
Each of the five intrinsic sub-types is nicely mapped to an IHC-defined sub-type [19]
[20] (Table 1.1) except for the normal-like tumors which share a similar IHC status with
the Luminal A sub-type and are characterized by a normal breast tissue profiling [21]. In
addition to this gene signature basis for classification of breast tumors, information such
as lncRNA and epigenetic data plays critical roles in tumor progression and classification,
providing novel perspectives on breast tumor sub-typing.
The luminal-like tumors are the most common sub-types among breast cancer. They
express hormone receptors, with expression profiles reminiscent of the luminal epithelial
component of the breast [21]. Luminal A tumors have higher expression of Estrogen
Receptor(ER)-related genes and lower expression of proliferative genes than luminal B
cancers [19] [22]. Luminal A tumors are commonly treated with endocrine therapy, while
luminal B tumors, which are more proliferative, with a combination of anti-proliferative
16
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Molecular Sub-type Prevalance IHC status Prognosis
Luminal A 23.7% ER+, PR+, HER2 -, KI67 - Good
Luminal B 52.8% ER+, PR+, HER2+/-, KI67+ Intermediate/Poor
HER2 over-expressing 11.2% ER -, P R-, HER2+ Poor
Basal-like 12.3% ER -, PR -, HER2 -, basal marker+ Poor
Normal-like 7.8% ER+, PR+, HER2 -, KI67 - Intermediate
Table 1.1: Classification and prevalence of the five breast cancer intrinsic sub-types with
associated clinical parameters
and hormonal treatment.
Basal tumors are composed of Estrogen Receptor(ER) negative, Progesterone Recep-
tor(PR) negative and Human Epidermal growth factor Receptor 2 (HER2) receptor neg-
ative (triple negative) tumors with high expression of basal markers (such as keratins 5,
6, 14, 17, EGFR) and proliferation related genes [21] [23]. Tumors characterized by basal
cytokeratin expression frequently also have low BRCA1 expression [24] and harbor TP53
mutations [25]. These cancers follow an aggressive clinical course and currently lack any
form of standard targeted systemic therapy. Given the triple negative receptor status,
basal tumors are not amenable to most conventional targeted breast cancer therapies,
leaving chemo-therapy as the only option in some cases in the clinic.
HER2 over-expressing breast tumors
HER2 over-expressing tumors are ER negative, PR negative and HER2 receptor positive
tumors, that show either an over expression of the HER2 receptor or mutation-induced
activation of the receptor. HER2 over expressing tumors are characterized by the over-
expression of other genes in the HER2 amplicon such as GRB7 and PGAP3 or mutation
in the TP53 gene [26]. Patients with these tumors have a poor prognosis.
HER2 is a member of the human epidermal growth factor receptor family of trans-
membrane proteins that respond to extra-cellular ligands by dimerization and trans phos-
phorylation of their intra-cellular domains, activating various signaling pathways in the
cell [27]including cell proliferation and survival. HER2 receptor positive cancers account
for 20-30% of all breast carcinomas [28] and show dependence on the HER2 oncogene for
survival.
These tumors, like others that show dependence on one or a few oncogenic proteins
or pathways to maintain their malignant phenotype, display a phenomenon called “onco-
17
Introduction
gene addiction”, a term first coined by Bernard Weinstein [29]. It provides a rationale for
molecular targeted therapy, whereby acute inhibition of onco-protein function by targeted
agents leads to “tumor shrinkage” and regression, associated with proliferative arrest,
apoptosis and/or differentiation. This response to targeted therapy is explained by the
concept of “oncogenic shock”. Oncogenic shock is defined as the acute imbalance of pro-
apoptotic and pro-survival signaling from an oncogenic kinase, upon drug-mediated kinase
inhibition [30]. A large number of antibodies and drugs that target specific oncogenes are
based on this concept.
Figure 1.3: Molecular approaches to HER2 targeted therapy. Figure from [31]
.
Several targeted therapies have also been developed for HER2-enriched tumors (Figure
1.3) and have successfully led to dramatically improved prognoses, increasing the overall
survival of Her2 positive patients [32]. This is seen especially in the case of the anti-HER2
antibody trastuzumab. But PTEN loss [33] and CXCR4 up-regulation [34] have been
implicated in trastuzumab resistance and commonly prevent complete tumor cell eradica-
tion. This incomplete anti-tumor activity of targeted therapeutics across a wide range of
cancers has been attributed to “residual disease”. Residual disease is therefore defined as
the population of tumor cells within a mostly therapy sensitive tumor, that survive initial
treatment. This leads to accumulation of drug resistant clones that cause an inadvertent
relapse that is more often than not, incurable and fatal [35].
18
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Taken together, although great progress has been made in identifying cancer-initiating
lesions and effective targeted therapies have been developed, tumor recurrence originating
from minimal residual disease is the most common cause of death along with metastatic
disease [36].
19
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1.2 Mouse models of human carcinomas
Advances in the genomic analysis of human cancers, has led to a much better understand-
ing of tumour evolution and heterogeneity, aided better classification of cancer subtypes
and helped to shed light on the role of the tumour micro-environment. However, large
sample numbers have to be obtained to analyse vaguely defined human tumour subtypes,
confounding lifestyle factors have to be considered and ethical hurdles have to be overcome
in order to obtain human samples and properly characterize disease in humans. Further,
a mechanistic analysis of tumour progression and therapy response is hard to achieve
with independent patient samples, since they reflect only a snap shot of these dynamic
processes. To this end, mouse models have proved to be an invaluable resource to system-
atically and reproducibly analyse mechanisms in tumourigenesis [37] [38].
Specifically, conditional Genetically Engineered Mouse Models(GEMMS) permit the
regulation of cancer inducing genes at a given time-point in a tissue specific manner allow-
ing us to study as well as visualize the outcome of drug treatment. They are engineered to
allow normal developmental processes in mice, enabling genomic manipulation that leads
to de novo tumour formation in the adult tissue. These conditional mouse models allow
tissue specific gene regulation either via Cre-ER mediated gene recombination upon ta-
moxifen administration or through the use of tetracycline inducible transgenes that permit
reversible control over target-gene expression [39]. They also serve as a tool to understand
late tumour stages by giving access to minimal residual disease following therapy and
homing metastatic cells, both cellular populations that largely remain elusive in patient
samples [40].
Organoid cultures of primary cells taken directly from GEMM mice are capable of
preserving the original architecture and signaling events within the tumour, allowing in-
depth mechanistic analysis. The establishment of 3D culture techniques [41] [42] [43]
started in the late 1980s and still continues for the development of growth factor cocktails
and scaffolds that mimic stem cell niches to allow the growth and long-term maintenance
of organoids [44]. Organoids grown from the primary cells harvested from GEMMs can
now be used to recapitulate tumourigenesis and study this process in great detail with the
help of multifaceted analysis, including ‘omics’ approaches, and fluorescence imaging – all
in a dish [45][46].
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TetO-cMYC/TetO-Neu/MMTV-rtTA mouse model
Our laboratory employs the TetO-cMYC/TetO-Neu/MMTV-rtTA tetracycline inducible
model of breast cancer together with a 3D culture approach to better understand the mech-
anisms of HER2 positive breast disease in conjunction with c-MYC activation. GEMM
mice in this model have two transgenes – oncogenes that play an important role in breast
tumorigenesis: c-MYC (MYC) which contains the truncated human gene with exon 2 and
3 [47] and activated rat Neu (Human ERBB2/ HER2 homolog)[48].
HER2 is a member of the EGFR family of receptors that is activated in 20-30% of
breast cancers. Her2 has been thoroughly characterized in breast carcinogenesis with many
therapeutics made available in the market for HER2 positive cancers [49]. The c-MYC
transgene encodes the transcription factor MYC that has been implicated in many primary
cancers in humans, mostly for its profound effect on tumor cell metabolism. It can be the
primary oncogenic protein in some human cancers like for instance, Burkitt’s lymphoma,
while in other types MYC is more often an “early-response” gene that is downstream of
other activated oncogenic pathways and signaling from ligand-receptor complexes. MYC
amplification has been closely linked with HER2 amplification and proliferative activity
in breast cancer [50] and by combining both oncogenes at the same time, we can model a
breast cancer sub-type with poor prognosis in the clinic [51].
Reverse tetracycline-dependent transcriptional activator (rtTA) regulates temporal ex-
pression of the oncogenes which are under control of the tetracycline-dependent minimal
promoter (TetO). Mouse mammary tumor virus long terminal repeat (MMTV-LTR) se-
quence enables spatial control of rtTA gene expression in the mammary gland of these
mice. The system is regulated by doxycycline (antibiotic from tetracycline class). Ad-
dition of doxycycline to the media (in primary 3D cultures) or in the animal diet allows
the rtTA inducer protein to bind to the TetO promoters controlling transcription of both
oncogenes. Supplemented with doxycycline, the mammary glands or organoids undergo
tumorigenesis, where tumor maintenance is dependent on the action of these two onco-
genes, mimicking the phenomenon of oncogene addiction. Upon removal of doxycycline
from the animal diet or 3D culture media, the oncogenes are switched off, mimicking per-
fect targeted therapy aimed at the driver oncogenes. The resulting population of cells
in this instance, have all suffered and survived oncogenic insult and thus resemble the
residual disease reservoir (detailed review in Section 3.1.1).
Previous efforts in the lab with this tetracycline inducible model of breast cancer have
led to the characterization of the mechanisms that these residual cells employed to relapse
in vitro. These cells showed a deregulated lipid metabolism resulting in ROS production
and DNA adduct formation. These features could be verified in the mouse model in vivo,
as well as in patient derived residual disease samples, collected after successful neoadjuvant
treatment [52]. These studies form the basis of the scientific questions asked and answered
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during my PhD.
In the following report, this very mouse model has been further adapted to mimic
stochastic tumorigeneisis of the breast (Project 1) and unravel mechanisms involved in
residual disease establishment (Project 2).
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TUMOURIGENESIS, ONE CELL AT A
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2.1 Introduction
Breast cancer, like all cancers, is thought to arise from the aberrant proliferation of a single
mutated cell within the epithelial layer [53]. The role of the tumour micro-environment in
breast cancer has been shown to be of extreme importance [54] and is explained by the sig-
nificant alterations in the surrounding stroma or tumour micro-environment of established
tumours [55]. However, although much research has gone into studying cell types like the
fibroblasts [56], macrophages [57], lymphocytes [58] and even the extracellular matrix [59]
that are found in the micro-environment, not much is known about the normal epithelial
cells that neighbour neoplastic cells.
Especially in the context of tumour initiation, one would expect that the normal ep-
ithelial cells could play a repressive role on tumour formation owing to the protective effect
of epithelial cell polarity [60]. Studies in the Drosophila model organism have played a
pivotal role in elucidating cell-polarity pathways in cancer. For example, the case of po-
larity proteins Lgl, Dlg and Scrib is well documented. These proteins, when knocked down
in Drosophila, result in neoplastic transformation and tumour-like growth in their larval
imaginal discs and brains [61]. Consequently, the re-expression of Dlg and Lgl proteins
in human tumour cell lines was shown to reduce viability and aggressiveness [62] [63].
These same polarity proteins have also been implicated, via loss of function, in primary
tumours from human patients [64] [65] [66] [67]. These results, taken together, imply that
cell polarity is disrupted in cancer, but the question is is this a by-product or a causal
mechanism of cancer?
In the context of oncogenes and their downstream activated pathways, there are a few
studies that shed more light on this matter. E6 oncogenes found in human papilloma virus
(HPV) target cell polarity proteins Dlg and Scrib for proteolytic degradation [68] [69] [70].
The ability to degrade these cell-polarity proteins correlates with the malignant potential
of E6 oncogenes. Similarly, in cancers caused by ErbB2 (also known as HER2) [71] [72]
[27], the Ras-PI3K-PLC pathway is activated to stimulate cell proliferation but it has been
shown to directly disrupt cell polarity through its interaction with the Par6-aPKC protein
complex [73]. These results support the idea that along with loss of tumour suppressor
genes, the disruption of cell-polarity mechanisms can play a causal role in tumour initia-
tion and is not just a by-product.
Similar to oncogenic pathways, there is an intimate connection between cell-polarity
pathways and tumour suppression. The von Hippel-Lindau (VHL) tumour suppressor gene
mutations have been uncovered in the development of hemangioblastoma, clear-cell renal
carcinoma and pheochromocytomas [74][75]. Wildtype VHL poly-ubiquitinates activated
aPKC trageting it for degradation [76] and regulates polarized microtubule growth and
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formation of primary cilia [77]. This function makes VHL an important regulator of cell
polarity because polarized growth of microtubules is crucial for cell polarization. Similarly,
the network regulation of Phosphatase and tensin homolog (PTEN) is also closely inter-
twined with cell polarity. PTEN negatively regulates the phosphatidylinositol 3-kinase
(PI3K) pathway by dephosphorylating the PI3K product, phosphatidylinositol (3,4,5)-
trisphosphate [PtdIns(3,4,5)P3] [78]. Spatial membrane segregation of PtdIns(4,5)P2 and
PtdIns(3,4,5)P3 is crucial for apical-basal cell polarity [79] because it effects the apical
localization of Annexin A2 (ANXA2), Cell division control protein 42 homolog (Cdc42)
and atypical PKC proteins.
Clearly, much has been revealed about the disruption of cell polarity in cancer via onco-
genes and tumour suppressors within a tumour. However, close to nothing is known about
the effect of healthy surrounding cells and their epithelial polarity effects on transformed
cells in an epithelial sheet. The major hurdle to studying these interactions between early
neoplastic cells and the normal epithelium is the inability to model stochastic tumourige-
nesis in tissues in a way that it can be followed on a single cell level.
Mouse models, especially in conjunction with 3D organotypic cultures, have been used
to study various stages of cancer [52, 80]. However, these mouse models are genetically
engineered to express oncogenes in all cells of the epithelial tissue and end up modelling
a tissue wide neoplastic transformation that is not analogous to human disease establish-
ment. It also fails to generate a certain heterogeneity at the early tumour initiation stages
that is a hallmark of cancer [81]; since all cells start to proliferate in a highly “trans-
formed” tissue environment instead of evolving and acquiring accruing genetic mutations
in a dynamic cancer initiation niche. Molecular, phenotypic, and functional diversity
within a patient’s tumour (intra-tumour heterogeneity) and among tumours from differ-
ent patients (inter-tumour heterogeneity) are features that can complicate diagnosis and
challenge therapy. So it is on prime importance that we uncover the molecular mechanisms
underlying early tumour initiation that give rise to heterogeneity.
In this project, we report the establishment of the very first stochastic breast tumouri-
genesis model using organoid cultures transduced with lentiviral vectors – a first step
towards modelling disease from its inception to gain insights into the largely unknown
healthy-tumour cell interactions in an intact epithelium.
Further, we report the optimization of Selective Plane Illumination Microscopy (SPIM)
to visualize the stochastic breast tumourigenesis events occurring in the 3D organoids.
Imaging of delicate primary cell organoids can be tricky and was possible only because
SPIM microscopy facilitates rapid imaging, with low photo-toxicity, greater penetration
depths and low scattering owing to illumination with a light sheet instead of a point
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Figure 2.1: Selective Plane Illumination Microscopy provides optical sectioning of the
sample using a laser light sheet for sample illumination. Only a thin slice of the sample is
illuminated perpendicular to the detection plane and image acquisition with this method
is faster and less photo-toxic than traditional confocal microscopy. Figure from [82]
.
source (Figure 2.1). SPIM imaging has a very low photonic load and therefore has been
used to visualize tumour dynamics in 3D cultures [83]. But to date, studies have been
limited in their cellular and temporal resolution. High resolution imaging can allow us
to track single cell dynamics. But this limits the time frame in which organoids can be
imaged without phototoxic effects[84]. Conversely, imaging primary organoids for longer
time periods requires an offset of temporal and cellular resolution that eventually does not
facilitate single cell fate tracking [85].
One of the drawbacks of SPIM imaging in 4D time-lapse is the generation of large
amounts of data that needs to be analyzed. Big-image data compatibility is still quite
limited in common image analysis tools used in bio-image analysis. Therefore, we devel-
oped a novel image analysis pipeline that allowed data handling and processing such that
the dynamic cell behaviors in developing tumours could be segmented and tracked over
time.
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2.2 Objectives
The main aim of this project was to establish a model of breast tumourigenesis that
better recapitulates the clinical situation in human disease. By initiating oncogenic trans-
formation in single cells in an intact epithelium, we aimed to better recapitulate tumour
initiation that is believed to occur in the human breast epithelium - one rouge cell that
acquires a genetic mutation and proliferates to establish tumourigenesis. We planned
to employ the 3D culture organoids of primary cells grown from TetO-Myc/TetO-Neu
mice. The oncogenic constructs in this mouse model are under the control of the TetO
promoter, that can only be activated to transcribe the oncogenes in the presence of the
rtTA inducer protein and doxycyxline. In order to activate the oncogenes in single cells
of the organoids’ epithelial layer, we planned to deliver the rtTA inducer via a lentiviral
construct. To further our aim of understanding the mechanisms of tumour establishment
in the intact epithelium, we wanted to image the organoids at a resolution in space and
time that would allow us to track single cells and their proliferative/apoptotic dynamics
while single cells were expressing oncogenes in the otherwise normal epithelial organoid.
To achieve these aims, we established the following objectives for the study:
1. Establish stochastic lentiviral transduction of single cells within organoids such that
they have been conferred the ability to express the c-MYC and Neu oncogenes, and can
be followed in culture by a fluorescence reporter protein (GFP).
2. Optimize imaging conditions necessary to record stochastic tumourigenesis from
the moment the oncogenes are induced in GFP marked cells (via doxycycline addition to
the media) and up to 96 hours after.
3. Implement a big image data analysis work-flow that facilitates the visualization
of terabytes of image data, further allowing the segmentation and tracking of the nuclei
(marked with GFP) within a stochastically transformed organoid.
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2.3 Results
2.3.1 Establishing a 3D in vitro model of stochastic breast tumourige-
nesis
The TetO-MYC/TetO-Neu/MMTV-rtTA mouse model is an inducible breast cancer model
and has been previously been shown to faithfully recapitulate human breast disease in our
group[52]. In this tri-transgenic model of tumourigenesis two oncogenes – Myc and Neu
–are spatially and temporally controlled in the mouse breast tissue. The oncogenic con-
structs have the tetracycline promoter TetO that allows expression of oncoprotein when
bound by the reverse tetracycline transactivator (rtTA) protein [86] in the presence of
the tertracycline analogue – doxycycline. Spatial control of oncogenes is achieved by the
MMTV promoter upstream of the rtTA construct than restricts rtTA protein expression
to the epithelial cells of the breast. Temporal control of the oncogenes is achieved by the
regulation of doxycycline in the animal diet. This way, the mice can be induced to ex-
press oncogenes in their breast epithelial tissue when they reach adulthood (8-10 weeks).
Primary mammary epithelial cells from this tri-transgenic mouse model have been grown
in 3D cultures and induced to express oncogenes in vitro [87, 48].
To model stochastic tumourigenesis and mimic the clinical situation better, we used a
modified version of the above-mentioned tri-transgenic system. We only retained the two
oncogenic constructs and bred bi-transgenic mice for experiments. We facilitated onco-
genic expression in a few cells by delivering the rtTA gene construct to random cells in
organoids in vitro, using a lentiviral delivery system developed in the lab.
Single cells digested from the mammary glands of the transgenic mice are seeded in
a 3D matrix and cultured to form hollow acini. After 3-4 days of growth, these acini are
digested out of the Matrigel matrix and mixed with lentiviral particles in solution. The
organoids and virus are seeded back into the 3D matrix and after a 3-day recovery period,
induced with doxycycline in the media, to facilitate expression of oncogenes in rtTA ex-
pressing cells (Figure 2.2).
Organoids grown from the mammary cells of bi-transgenic mice are transduced with
the Inducer-reporter (pLenti-rtTA-GFP) lentiviral particles that express rtTA in single
cells and mark them with H2B-GFP. Introducing doxycycline into the media expresses
c-MYC and Neu oncogenes in the randomly transduced subset of cells in the organoid.
When and if tumours are established in these organoids, they develop in the presence
and of normal epithelial cells in their micro-environment. The random transduction and
subsequent transformation of single cells in these acini (representing normal epithelia) is
aligned more closely with the patient situation and represents a stochastic model of tu-
mourigenesis.
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Figure 2.2: Schematic representation of the mouse models and the in vitro culture meth-
ods used. Organoids are grown from single cells harvested from the mammary glands of
either bi-trangenic (B) or tri-trangenic (T) mice, transduced with lentiviral particles in
solution and re-seeded into 3D cultures. Doxycycline is added to the media to induce
the expression of oncogenes in cells expressing rtTA. B mice have the c-MYC and Neu
oncogene constructs in their genome. These oncogenes are activated in single cells infected
with the Inducer-reporter (pLenti-rtTA-GFP) lentiviral particles, in the presence of doxy-
cycline — modelling stochastic breast tumourigenesis (bottom panel). T mice have the
rtTA transducer construct along with the oncogenes and all cells in T organoids can be
induced to express oncogenes in 3D culture in the presence of doxycycline. T mice infected
with Reporter (pLenti-NULL-GFP) lentiviral particles are used as infection controls (top
panel). Both viral particles mark single cells in the organoids with H2B-GFP.
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As transduction controls, organoids grown from the mammary cells of tri-transgenic
mice were transduced with the Reporter (pLenti-GFP) lentiviral particles that simply
mark single cells with H2B-GFP. Since all cells in the tri-transgenic organoids have the
rtTA construct, introducing doxycycline into the media expresses c-MYC and Neu onco-
genes in the whole organoid. All cells proliferate rapidly, and the monolayer epithelial
organoids form tumours with multiple layer rims. The tumours are established in a com-
pletely tumourigenic environment and thereby this system models tissue wide tumourige-
nesis.
Since the rtTA protein expression is driven by a different promoter in both systems, the
doxycycline concentration used in the stochastic system was normalized to the established
concentration of doxycycline used to induce organoids of the tissue wide system. Quantifi-
cation of c-MYC and Neu mRNA in single cells across both systems was performed using
qPCR, at various doxycycline concentrations (see Figure 2.3). The doxycycline concentra-
tion used to induce oncogenic expression in the tri-transgenic system has been optimized
at 800 ng/ml by previous efforts in the group. Based on the qPCR quantification, 600
ng/ml of doxycycline in the stochastic system leads to similar expression of the oncogenes
in single cells of the stochastic system. This concentration was used in all further experi-
ments involving the stochastic system.
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Figure 2.3: Fold changes in the mRNA expression of transgenes, Myc and Neu in trans-
duced mammary epithelial cells of B mice (n=2) infected with Inducer-reporter virus or
T mice (n=2) with Reporter virus. The doxycycline dosage of 800 ng/ml (T800) is well
established in the T cells and was used as control to normalize the gene expression, and
also to determine the dose for transduced B cells (600 ng/ml). Data represented as mean
±SEM ; ∗P < 0.05.
Immunofluorescence staining of PFA fixed 3D gels, shown in Figure 2.4 validate the
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Figure 2.4: Representative immunoflourescence staining images of fixed 3D gels with B
organoids transduced with Inducer-reporter virus or T organoids transduced with Reporter
virus before induction (top), 24 hours post induction and (middle) 72 hours post induction
(bottom) with doxycycline. c-MYC oncogene (magenta), GFP expressing transduced cells
(green), DAPI nuclear stain(blue). Scale bar, 10 µm.
expression of MYC in only the transduced cells of the bi-transgenic organoids (stochastic
system). A co-localisation of MYC protein is seen in the cells transduced with the Inducer-
reporter virus (marked with H2B-GFP). In contrast, the MYC stain is positive for all
cells in the tri-transgenic organoids (tissue wide tumourigenesis system). Here the cells
expressing GFP are simply marked by the Reporter virus.
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2.3.2 Live organoid imaging reveals early tumour dynamics in 4D at
single cell resolution
To visualize the establishment of tumours in the otherwise healthy epithelial rim and
analyse their evolution on a single cell scale, we crossed the fluorescence reporter H2B-
mCherry into the bi-transgenic and tri-transgenic mouse lines using a R26-H2B-mCherry
line. Lentivirus-transduced organoids grown from these H2B-mCherry lines were then
imaged during induction using Selective Plane Illumination Microscopy (SPIM). Light
sheet microscopy employs a sheet of laser light to scan the sample. In comparison to
confocal and spinning disc microscopy methods, this offers faster acquisition, high sample
penetrance and a low photonic load. All the imaging experiments for this project were
performed on the InVi SPIM microscope (Luxendo Light-Sheet, Bruker Corporation).
Sample mounting for the InVi SPIM is performed using a custom-made sample holder.
The holder has a trough with a slit at the deep end where the sample is placed for
imaging. The sample is placed on a 25 µm thin membrane which is glued onto the sample
holder using a mould. We transferred gel slivers containing transduced bi/tri transgenic
organoids onto the FEP sheet of the holder and induced oncogenic expression by adding
media supplemented doxycycline to the sample holder (Figure 2.5).
a. b.
 
1cm
500um
c.
Figure 2.5: (a) The FEP membrane is glued onto the sample holder with the help of a
mold and bio-compatible glue. (b) Gel slivers are transferred to the FEP sheet trough in
the sample holder (c) Gel slivers are overlaid with fresh matrigel to prevent drift during
imaging. Media is added after the upper matrigel layer solidifies.
The process of tumour establishment in both systems was then recorded in 4D. Images
were recorded as 2D planes ranging from 100-500 in number, depending on the organoid
size. Each 3D stack of planes was recorded in 2 channels - mCherry (all cells) and GFP
(transduced cells). Depending on the duration of the time lapse imaging, 450-600 image
stacks (equivalent to 72-96 hours) were recorded per organoid at 10-minute intervals. A
series of optimization experiments, involving different laser powers, exposure times and
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z-step sizes yielded laser powers of 13.1 microWatts for 488 nm and 36.4 microWatts for
594 nm, 100 millisecond exposure time per frame and 1µm z-spacing between frames to
be optimal for long term imaging (96-120 hours) without photo-bleaching or photo-toxic
effects on growth.
Tri-transgenic organoids transduced with the Reporter virus showed high cell prolifera-
tion and rapid expansion when the oncogenes were expressing in the cells. The single layer
organoid rims sustained high cell proliferation to result in the filling of the lumen. The
tumour organoids have multiple cell layers and pronounced apoptosis that is associated
with tumour evolution (Figure 2.6a).
In contrast, the bi-transgenic organoids transduced with the Inducer-reporter virus
showed a dual phenotype during imaging. Some lentivirus transduced cells within organoids
proliferated under the oncogenic push and established small tumour foci within the organoid.
They sustained high proliferative rates in their niches within the normal epithelium and
started to fill in the hollow lumens. Other lentivirus-transduced cells did not seem to pro-
liferate at all. They remained integrated in the normal epithelium and did not proliferate
or establish any tumourigenic foci within the organoids (Figure 2.6b).
To exclude for imaging artefacts, we performed immunofluorescence staining on PFA
fixed 3D sister gels grown in the incubator (Figure 2.7). Consistent with the light-
sheet movies, 3D gels grown in the incubator showed a similar dual phenotype for the
bi-transgenic (stochastic tumourigenesis) organoids while the tri-transgenic (tissue wide
tumourigenesis) organoids consistently formed tumours upon oncogene induction.
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Figure 2.6: 3D images of selected timepoints during live-cell time-lapse microscopy of
induced T organoids transduced with Reporter virus (a) or B organoids transduced with
Inducer-reporter virus (b). All cells in the organoids express H2B-mCherry (magenta)
and only cells transduced with lentiviral particles express H2B-GFP (green). Imaging
was started 24 hours after oncogenic induction with doxycycline. In (b) the upper panel
shows the proliferative phenotype seen with stochastic transformation, whereas the lower
panel shows the non-proliferative phenotype observed in some stochastically transformed
organoids. (Imaging conditions: H2B-mCherry 594nm Ex, 610 LP Em; H2B-GFP 488nm
Ex and 497-554 nm Em). Scale bar, 20 µm.
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Figure 2.7: Representative immunofluorescence staining images of PFA fixed 3D gels with
(a) T organoids (transduced with Reporter virus) and (b) B organoids (transduced with
Inducer-reporter virus), before induction and 96 hours post induction with doxycycline.
Polarity markers include alpha-6-Integrin (magenta) and ZO-1 (yellow). Transduced cells
are marked with GFP (green) and nucleus is counter-stained with DAPI (blue). Scale bar,
20µm.
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2.3.3 Development of big-image data compatible analysis workflow al-
lows tracking of cell lineages during early tumour formation
To analyse the 3D time-lapse movies recorded at the InVi SPIM, we developed an im-
age analysis workflow using Fiji plugins[88] and Imaris (commercial software[89]). The
workflow was designed and developed with the help of Christian Tischer at the Center for
Bioimage analysis (CBA) at EMBL, Heidelberg.
The establishment of stochastic tumours in bi-trangenic organoids transduced with
the Inducer-Reporter virus was recorded in two channels - H2B-mCherry—all cells in
the organoid, H2B-GFP—transduced cells within the organoid. The raw files from the
microscope in .h5 format were streamed using the Big Data Processor (BDP) Fiji plugin
[90]. The Fiji plugin provides a virtual viewer that allows lazy loading of the image stacks
in 2D for visual inspection. The “Chromatic Shift Correction” tab of the BDP was used to
align the two-channel data. The “Cropping” tab of BDP was used to crop out empty/black
pixels and remove empty planes. The “Saving” tab of the BDP was used to bin images (3
x 3 x 1 in x, y, z), perform 8-bit conversion and convert .h5 files from the InVi SPIM into
an Imaris compatible multi-resolution file format (.ims) for further analysis (Figure 2.8).
Lazy Loading Chromatic Shift
Correction
Cropping Binned Saving
Dataset Size : 1264.2 GB
Before
After
Before
After
Dataset Size : 15.5 GB
Figure 2.8: The Big Data Processor Fiji plugin was employed for pre-processing light-sheet
microscopy images. Two-channel raw images were lazily loaded in 2D slice mode for visual
inspection. Channel shift correction was performed to align the two channels. Then, the
whole dataset was cropped in x,y,z to remove black pixels and empty planes. The cropped
dataset was then saved in an 8-bit Imaris format with 3x3 binning applied in x and y.
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The lentivirus-transduced cells marked with H2B-GFP showed heterogeneous mor-
phologies and varying intensity textures in the time-lapse recordings. This makes it diffi-
cult to segment them using conventional thresholding approaches, such as the ones in-built
in Imaris. Therefore, we used a trainable segmentation approach to convert the raw in-
tensity values into pixel probability maps, using the Fiji plugin Context Aware Trainable
Segmentation (CATS) [91]. We trained three pixel classes: background, nucleus center
and nucleus boundary on the input files (H2B-GFP channel images). On these we drew
about 20 (background), 120 (nucleus center), 100 (nucleus boundary) labels distributed
across the different time-frames of the movie for training the classifier. After feature com-
putation and training of a Random Forest classifier the whole dataset was processed on
EMBL’s high performance computer cluster. The nucleus centre probability maps were
then exported from CATS and added as an additional channel to the converted intensity
data in the processed .ims files (Figure 2.9).
The data were then loaded into Imaris and visualized, segmented and tracked in 3D
(Figure 2.10) The “surfaces” function on Imaris was used to segment the cell nuclei using
the nucleus centre probability map channel. Probability maps were manually thresholded
using a surface smoothening parameter of 0.3 µm; the minimum quality parameter for
seed points was set to 0.1, and object splitting was applied for objects larger than 5.5 µm.
Objects with volumes less than 20 µm3 were excluded.
Segmentation accuracy was assessed by analyzing wrongly segmented cells. In Figure
2.11 an example organoid, whose transduced cells were segmented, is shown at 4 time
points, counting: True Positives (correctly segmented cells, highlighted in green), False
Merges (two cells merged as one, highlighted in orange), and False Splits (one cell split in
two, highlighted in purple). Unidentified cells are indicated as False Negatives and Ground
Truth indicates the actual number of cells at each time point. Majority of errors in the
object segmentation were clearly the false merges, where two cells were segmented as one.
This kind of error is frequently not sustained in the previous or following time-points and
hence, an increased gap size parameter of the tracking algorithm should not affect tracking.
This was verified by tracking the objects identified using Imaris’ Lineage tracking function
with a maximum distance between objects in subsequent time-points limited to 10 µm and
a maximum gap size between identification of the object in a particular track limited to 10
time points. The final track trees of transduced cells within the organoid were corrected
manually within Imaris, e.g., excluding apoptotic cells and auto-fluorescent debris.
In Figure 2.12 we see an example bi-transgenic organoid transduced stochastically by
the Inducer Reporter virus. The implementation of the analysis workflow allowed us to
track the evolution of single cells when induced with doxycycline over 3 days. Clearly,
single transduced cells within one organoid show a difference in proliferation and cell fate
as indicated in the representative tracks.
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Trainable segmentation
Pixel probability map overlay
Figure 2.9: The CATS Fiji plug-in was used to generate pixel probability maps for H2B-
GFP images. Left panel shows the manual training done by drawing labels on the dataset
to classify pixels into 3 classes – background(grey), nucleus boundary (red) and nucleus
center (green). The right panel shows the pixel probability output for all three classes
overlaid on the intensity data. Only the pixel probabilities from the nucleus center class
were exported from CATS and linked to the Imaris data set for further segmentation and
tracking on Imaris.
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Figure 2.10: Schematic representation of the big-image data analysis pipeline developed
to analyze the light sheet microscopy images. Images are acquired in two channels (H2B-
mCherry in magenta and H2B-GFP in green) at 10-minute intervals for 3-4 days. Big
Data Processor Fiji plugin is used to pre-process the raw images and CATS Fiji plugin
is used for generation of pixel probability maps. Image pixels of the H2B-GFP images
are classified into background (black), nucleus centre (green), nucleus boundary (blue)
classes by manual training. Processed raw images along with the probability maps from
the nucleus center channel (green) are exported to Imaris for 3D visualization, nuclear
segmentation and single cell tracking.
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True Positives 17 52 69 74
False negatives 0 1 0 0
Ground Truth 17 61 82 76
T = 1 T = 447T = 300T = 150
H2B-mCherry
True Positives
False Merges
False Splits
0 4 6 1False Merges
0 0 2 0False Splits
Figure 2.11: Image panels show the H2B-mCherry signal (magenta) along with the seg-
mented H2B-GFP cells of an organoid at four equidistant timepoints. Segmentation ac-
curacy was assessed, counting: True Positives (correctly segmented cells, highlighted in
green), False Merges (two cells merged as one, highlighted in orange), and False Splits (one
cell split in two, highlighted in purple). Unidentified cells are indicated as False Negatives
and Ground Truth indicates the actual number of cells at each timepoint. The average
True Positive to Ground Truth ratio for the four time-points is 0.92. Scale bar, 20 µm.
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Figure 2.12: Representative B organoid transduced with the Inducer-reporter virus at the
beginning of the time-lapse (24 hours post induction with each transduced cell surface
rendered with Imaris) and the organoid at the end of the time-lapse (∼76 hours post
induction with doxycycline). The bottom panel shows the lineage trees of each individual
cell over the time lapse recording. Lineage trees of single cells are grouped into proliferative
(highlighted in red, orange) and non-proliferative (highlighted in blue) cell clusters. Color
coding of each cell maintained in all panels. Scale bar, 15um.
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2.3.4 Feature analysis of lentivirus-transduced organoids indicates that
the origin of tumours may be in cell clusters and not in single
transformation events
The implementation of the image analysis workflow on the time lapse recordings shows
us a variation in proliferation rate and cell fates of bi-transgenic organoid cell transduced
with the Inducer-reporter virus. This difference in behavior of single transduction events,
even among cells of the same organoid, in turn affects the establishment of tumour foci
within the healthy epithelia. Why do single cells expressing the same oncogenes behave
differently? Observation suggested that the cells that undergo transformation in proximity
with each other seem to be successful in establishing tumour foci. It could also be that
the more cells transduced in an organoid, the higher the chances of tumour formation. To
better understand the parameters that positively affect a transduced cell in the stochastic
tumourigenesis model to start proliferating and establish a tumour within a normal ep-
ithelium, we extracted 9 features of the organoids (n=20; Table 5.1) and all the transduced
cells in these organoids (n=150) at the start of the imaging.
Basing the analysis of the observation that “proximity” might be the deciding factor
for tumour formation, first, we exported the center of mass coordinates of all cells of the
organoid so they could be represented in a 3D space for distance calculations. Next, we
aimed to cluster the cells that were transduced. We computed the pairwise Euclidean
distances between all oncogene-expressing cells in an organoid and applied hierarchical
clustering with complete linkage. Clusters were identified automatically by cutting the
branches of the trees using the dynamic tree cut algorithm [92]. A cluster was defined as
a group of transduced cells that are closer to each other than to other transduced cells
within the same organoid. So logically, a cluster can be composed of a single cell if this cell
is comparatively isolated from other transduced cells. Mathematically, a “cluster volume”
can be calculated as the volume of the sphere centered at the center of mass of the cluster
with diameter equal to the distance between the two farthest oncogene-expressing cells of
the cluster. This served as boundary parameter for estimation of features involving the
state of the immediate micro-environment of single transduced cells.
Then we asked, what features of this organoid could play a role in tumour promotion?
(1) Number of cells in the organoid?
(2) Cell density of the organoid’s epithelial layer?
(We expressed “cell density” as the ratio of number of cells to organoid surface area.
Organoid surface area was computed by assuming the organoid is a sphere with diameter
equal to the distance between the two most distant cells)
(3) Number of oncogene-expressing cells in the organoid?
(4) Number of cells (including both oncogene-expressing and normal cells) in the cluster
volume?
(5) Number of oncogene-expressing cells in the cluster?
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Figure 2.13: Schematic representation of the 9 features of stochastically transformed cells
extracted at the beginning of time lapse imaging. These features were assessed for their
impact on tumour cell proliferation within B organoids transduced with the Inducer-
reporter virus using logistic regression.
(6) Average pairwise distance between all cells in the cluster volume?
(7) Average pairwise distance between oncogene-expressing cells in the cluster?
(8) Fraction of oncogene-expressing cells in the cluster volume
(9) Number of contacts between oncogene-expressing cells in the cluster?
(Two cells are presumed in contact if they are less than the average cell diameter + 2
standard deviations apart).
The above nine features were further tested for their effect on tumour formation (Figure
2.13).
Since all transduced cells were tracked over time, using the previously described big-
image data compatible workflow, we were able to associate each cluster with a tumour
outcome (if any of its cells lead to tumour formation). To identify which features were
linked to this outcome, we took an information-theoretic approach to model selection.
We fitted a logistic regression model for all possible linear combinations of features
and selected the best model based on the Akaike information criterion (with correction for
small sample sizes) [93]. This model included only three contributing features: (5) Number
of oncogene-expressing cells in the cluster (3) Number of oncogene-expressing cells in the
organoid and (4) Number of cells in the cluster. Additionally, as indicated in Figure 2.14,
p-value calculations show that only the Feature (5) Number of oncogene-expressing cells in
the cluster contributed significantly to tumour formation with an odds ratio of 9.1. This
means, that each additional transduced cell in a cluster increases the odds of this cluster
forming a tumour by 9.
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Figure 2.14: Best logistic regression model for all possible linear combinations of features
based on the Akaike information criterion. Coefficients (represented as odds ratios) of
the three features included in the best logistic regression model, colored horizontal bars
represent the 95 percent confidence interval of the estimate. ** indicates p-value (of having
no effect) less than 0.01, * indicates p-value less than 0.05. The vertical grey line indicates
the position of no effect.
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Figure 2.15: Alternate regression model fitted including all features using LASSO regu-
larization. Numbers correspond to features shown in 2.13
Additionally, we also built a logistic regression model including all features (not just
the best combination) and using LASSO regularisation to select features. The output of
this model shown in Figure 2.15 confirmed our previous results that only the Feature (5)
Number of transduced cells in the cluster shows a positive effect on tumour establishment.
This is further demonstrated by representative organoids shown in Figure 2.16. Here,
the cells that are likely to proliferate, cluster together at the start of the time lapse imaging
and the non-proliferative cells are more sparsely located within the organoid, as shown in
the hierarchical clusters. These data confirm our hypothesis that there is indeed a higher
chance of tumour establishment by single transduced cells if they are in close proximity
to other transduced cells.
45
Unravelling stochastic tumourigenesis, one cell at a time
 ● ● ● ●
● ●●●●● ● ●
● ● ● ● ● ●
T = 74:50 hh: mmT = 00:00 hh: mm
T = 00:00 hh: mm T = 75:00 hh: mm
T = 74:50 hh: mmT = 00:00 hh: mm
Figure 2.16: Representative B mammary organoids stochastically transduced with the
Inducer-reporter virus and induced with doxycycline. Left panels show organoids 24 hours
post induction. Color highlights indicate clusters of transduced cells identified from hierar-
chical clustering (shown in middle panels) with proliferative clusters highlighted in orange
and non-proliferative clusters highlighted in blue. Right panels show the same organoids
72-76 hours post induction. Scale bar, 20µm.
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2.4 Discussion
The rationale for this study, as explained earlier, is the inaccessible mechanisms of early
breast cancer initiation in an intact epithelium. In humans, the detection of the earliest
events in cancer initiation is limited by its cellular scale and the lack of detection tech-
nology. Even in mouse models of breast cancer we are able to achieve only a tissue wide
neoplastic transformation, where the oncogenes are being expressed in all cells of the mam-
mary epithelium. To truly understand how single transformed cells survive and proliferate
in a healthy epithelilal cell layer, we established the first ever in vitro stochastic model of
breast cancer using lentiviral transduction of single cells in murine mammary organoids
(Objective 1). Further, to explore the processes underlying tumor initiation and the role
of normal epithelium in these processes, we established live cell imaging of these organoids
such that we could acquire images at the resolution and time interval needed to track
single cells in a complex 3D system (Objective 2). Finally, we developed and optimized
an image analysis workflow that could process big image data files generated during light
sheet microscopy, and allowed for nuclear segmentation and tracking (Objective 3).
Modelling stochastic tumourigenesis in murine mammary organoids has shown, for
the first time in 3D organoid cultures, that the normal epithelium has a profound effect
on early tumour establishment. Light sheet imaging over four days, following every cell,
in conjunction with feature analysis and mathematical modelling bolster the observation
that small groups of oncogene-expressing cells within the healthy organoid are much more
successful at establishing tumourigenic foci in comparison to isolated oncogene express-
ing cells. This indicates that a possible proximity controlled paracrine signalling network
is established within the transduced cells that allows them to proliferate and evolve as
tumours. Conversely, the inability to proliferate, that seen in the isolated oncogene ex-
pressing cells, is indicative of the “repressive” effect of the normal epithelium that has
been reported before via paracrine soluble factors and even microRNAs [94].
The interaction of tumour cells with the immediate microenvironment has been sub-
ject of extensive studies with regards to immune cells [95] and other tumour associated
cell types [54], however, the interaction with the normal neighboring cells has not been
explored in real time using an organotypic mammalian model system. Rather, questions
of cell competition in heterogenous tissues have mainly been addressed in either 2D cul-
ture systems or in the Drosophila wing [96]. Organ-specific mammalian cell types that
self-organize in a manner similar to the in vivo situation can now be studied in specialized
organoid 3D culture conditions in vitro [44]. Furthermore, these organoids can be used to
model disease and serve as an alternative system for drug testing that better recapitulate
effects as compared to conventional 2D cell culture [80] [97].
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The established paradigm that cancers in epithelial tissues arise from single mutated
cells has been challenged by these findings and the cell of origin of tumours has been found
to be cell clusters of origin. Further characterization and multi-omics analysis of this model
will validate this hypothesis in the future. Apart from the tumour cell of origin debate,
this system has the ability to further investigate the importance of epithelial polarity pro-
teins on the establishment of breast tumour progression and metastasis. For example,
the loss of important polarity proteins like Par3 and Par4/LKB1 have highlighted their
function as non-canonical tumour suppressors in breast tumourigenesis [98, 99]. However,
other reports on the tumour initiating potential of Par3 [100] and the alternative pathways
triggered by the loss of the Par4/LKB1 polarity protein[101], indicate that they could be
drivers of tumour formation. Clearly, to better interrogate such conflicting reports, there
is a need for a more detailed analysis, employing a model system that does not show mod-
ification of all cells in the tissue. To this end, our new stochastic tumourigenesis system
can be employed to settle conflicting reports. Introducing a knockout phenotype of any of
the epithelial polarity proteins into the mouse model via somatic mutation or additional
lentiviral delivery is an option that can be explored.
The amenability of this system to interference with small molecule inhibitors, viral
shRNA vectors and genomic editing has the potential to further our understanding of
the mechanisms important during tumour initiation. The ability to distinguish marked
tumour cells from the normal epithelium will now allow us to perform single cell RNA
sequencing analysis on select sorted cells. This will help delineate the signalling networks
within the immediate tumour micro-environment.
Taken together, we strongly believe that our integration of a true stochastic tumour
model with the ability to image single-cell fates will successfully bridge the gap between
genetically modified model systems and the clinical situation, helping gain novel insights
on early breast cancer events .
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2.5 Conclusions
The in-depth characterization of early tumor initiation events in breast cancer, that give
rise to tumor heterogeneity and early dissemination of metastatic cells, have not been fully
characterized. The gap in our knowledge of these early initiation events is a result of lack
of samples at this stage - a black box of patient material. Modelling the conditions of
early tumor initiation using mouse models also fails to recapitulate the human situation,
driving a tissue wide neoplastic phenomenon instead.
Adapting an already well characterized oncogene inducible mouse model of breast can-
cer, we developed an in vitro organoid system that is truer to the human situation and
can activate oncogenes in single cells of the healthy organoid epithelium via lentiviral
transduction. Characterization of this in vitro stochastic tumorigenesis system helped us
observe that not all transformed single cells in the organoid epithelium had the capacity
to proliferate and establish tumorigenic foci. Some cells resisted proliferation over many
days of oncogene exposure unable to expand despite confirmed onco-protein localization.
In an effort to better understand this dual phenotype of single transformed cells we
then established live cell imaging of these stochastically transformed organoids in 3D over
3-4 days using light sheet microscopy. Overcoming light sheet data limitations, we also im-
plemented an image analysis workflow that allowed us to track single cells as they evolved
within the organoid. Feature analysis of of over 150 transformed cells in 20 organoids
showed that the cells in clusters were more likely to form tumors than isolated oncogene-
expressing cells.
These results point to a proximity controlled signalling network between single trans-
formed cells that is imperative to the growth and establishment of tumors within healthy
epithelia. As a result, this study provides a whole new perspective on cell of origin of
tumors, postulating rather a cell cluster of origin governed by signals from its healthy and
neoplastic neighbours. What these signals are and how they are transmitted can now be
explored using this model. Clearly, the role of the neighbouring healthy epithelial cells via
cell polarity mechanisms needs further investigation as does the transcriptomic profiles of
all cells in the cancer initiation niche, so that we can better understand early tumor events
in the breast.
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3.1 Introduction
3.1.1 Minimal Residual Disease
Definitions from the lab and the clinic
In the present age of precision medicine, when molecular dependencies of various tumours
are being unraveled by sequencing and functional assays, a panoply of therapeutics that
target kinases, transcriptional modifiers, immune checkpoints and other cancer vulnerabil-
ities are being used in the clinics with excellent short-term prognosis. Consequently, the
response to therapy has greatly improved for patients whose tumours have been profiled
extensively, such as those with chronic myeloid leukaemia (CML), KIT proto-oncogene
receptor tyrosine kinase (KIT)-mutated gastrointestinal stromal tumours [102], epider-
mal growth factor receptor (EGFR)-mutated or ALK receptor tyrosine kinase (ALK)-
rearranged lung adenocarcinoma [103] [104][105] and BRAF-mutated melanoma [106][107].
Most patients with these diseases now achieve what is known as a complete remission (CR).
CR in patients with cancer is traditionally defined as the absence of a visible tumour by use
of sensitive radiological imaging (PET, MRI or CT). This means, CR, whether achieved
by chemotherapy, targeted therapy, radiation, surgery or a combination, typically requires
>99% (that is, >2–3 log10) reduction in tumour burden [108][109]. In a hypothetical
patient with five metastatic lesions averaging 2 cm3 each, this would equate to a reduc-
tion from approximately 1010 tumour cells to <108 tumour cells [110]. This implies that
despite the high sensitivity of various cancers to treatment, some residual cancer cells
persist anyway. These persistent cells have been reported to lead to tumour recurrence
and treatment failure. As such, this cell reservoir surviving these precision therapies is
called “minimal residual disease”. These residual cancer cells can persist locally, in the
bloodstream as circulating tumour cells or in distant organs as disseminated tumour cells
[111]. But just because cells remain in the patient body after therapy, does not necessary
mean they will cause relapse. In some cases, residual cells share phenotypic similarity (for
example, histologic appearance and lineage markers) and genetic heritage (for example,
truncal mutations and chromosomal rearrangements) with the original tumour cells, but
they are not fully malignant [110]. It is therefore probably only the “malignant” reservoir
of residual cells that harbor somatic alterations and/or phenotypic alterations resembling
a tumour that need to be targeted to prevent tumor recurrences. This is the therapeutic
challenge of the precision age.
Mechanisms of establishment of minimal residual disease.
Based on its definition using the complete remission(CR) theory mentioned above, the
residual disease cells left behind at CR stage may seem an arbitrary selection – stochasti-
cally unaffected by the therapy method. However, breast cancer minimal residual disease
studies in mouse models [112] for BRCA1-deficient breast cancer, show that repeated
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treatments with the drug could not limit the residual cell reservoir completely even at
titrated doses and higher therapeutic duration. This hints towards there being defined
biological mechanisms that favor the survival of residual tumour cells.
Early observations in the clinical situation suggested there was a subset of tumour
cells that had somehow mutated and was insensitive to drugs. These insensitive cells
were postulated to be the only survivors of therapy. This was supported by findings in
lung cancer patients [113] where residual cells developed a mutant allele of the oncogene
being targeted. Another common mechanism of therapy evasion was the activation of
an alternative signaling pathways as decribed in great detail in Niederst and Engelman,
2013 [114]. These mechanisms were coined as “secondary resistance” mechanisms and are
still being unraveled today. For example, mutant BRCA1 or BRCA2 breast and ovarian
cancer relapses have been found to have secondary mutations of the BRCA1/2 genes that
apparently restore BRCA1/2 function [115][116]. These relapse tumours with secondary
resistance no longer respond to the previously successful Poly (ADP-ribose) polymerase
(PARP) Inhibitors [117][118] [119]and DNA cross-linking drugs [120].
Indeed, the identification of secondary resistance mechanisms is of extreme importance
to develop therapeutic interventions for late stage patients. But therapy evasion cannot
be the only mechanism used by cells to survive in a tumour under attack. This is proven
by clinician statements that patients with recurrent disease respond again when the ini-
tial therapy is repeated. These cases cannot be explained by the “drug insensitive cell
subset” theory of residual disease establishment. These observations point to cell intrinsic
molecular mechanisms – for example, entering senescence to evade drugs targeting prolif-
erative cells — that may cause residual disease in these patients. In addition, dynamics
of the tumour micro-environment such as fibroblast signaling, immune cell intervention,
extra-cellular matrix effects and the vascular network may play a role. Therefore, residual
disease establishment mechanisms may be attributed to cell intrinsic and cell extrinsic
factors [121]
53
Quest for the Achilles’ heel in breast cancer residual disease
Cell-intrinsic mechanisms of establishment of minimal residual disease.
CSC conferred resistance
The cancer stem cell (CSC) tumour model postulates that there is an inherent hierar-
chy within tumours[122] – growth depends on a few cancer stem cells that are capable of
self-renewal. According to this model these self-renewing CSCs are inherently more drug-
or radiotherapy-resistant and are therefore responsible for local tumour recurrence and
distant metastases appearing after initial treatment [123][80]. Pro-survival mechanisms
in CSCs include: elevated apoptosis resistance, drug-efflux pumps, enhanced DNA repair
efficiency and epithelial to mesenchymal transition (EMT)[124]. Another interesting ob-
servation is the increased re-population rate of CSCs during radio- or chemotherapy [125].
Following initial therapy response, an accelerated re-population during successive cycles
of therapy causes tumour relapse in the absence of any change in the intrinsic sensitivity
of the tumour cells. Accelerated growth of tumour-repopulating cells here is attributed to
re-oxygenation of cells upon reduction of tumour burden or the release of prostaglandinE2
(PGE2) from tumour cells killed by chemotherapy [126].
Metabolic dependency Studies in an inducible mouse model of pancreatic ductal
adenocarcinoma (PDAC) has shown that the residual cells were less glycolytic and more
dependent on mitochondrial pathways for energy production. Accordingly, surviving cells
showed high sensitivity to oxidative phosphorylation inhibitors, which successfully blocked
tumour relapse in this model. Intriguingly, residual cells had a distinct metabolic profile
and this was considered critical for the survival of these cells[127].
Autophagy
Autophagy or ”self-devouring” is the natural, regulated mechanism of the cell that
removes unnecessary or dysfunctional components [128]. It allows the orderly degradation
and recycling of cellular components. Surprisingly, this process has been shown to help
the establishment of residual disease in various cancers. For example, in an osteosarcoma
xenograft model, the dormant state correlated with enhanced autophagy and the pres-
ence of extracellular glutamine [129]. Inhibiting autophagy or depleting glutamine was
sufficient to increase chemotherapeutic sensitivity in this model for osteosarcoma. Since
autophagy is executed by the activity of lysosomes, sequestration of hydrophobic weak
base chemotherapeutics in the lysosomes may be the mechanism of therapy evasion [130].
Cell Senescence
Therapy Induced senescence (TIS) is another concept that could explain MRD estab-
lishment [131]. It is frequently seen in the form of giant polyploid cells that occur at the
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primary site after initial intervention. These cells are formed because of cancer cells that
enter a cell cycle arrest by suspending their mitotic activity while maintaining DNA dupli-
cation [132]. The DNA endoreduplication generates polyploid cells which can survive for
weeks as non-proliferating mono-or multi-nucleated giant cells. A study also showed that
viable progeny can arise from polyploid TIS cells in a process that strikingly resembles
that of daughter cell budding exhibited by many protozoans. This could be because of an
increased expression of cyclin-dependent kinase 1 (CDK1)[133].
Chromatin remodelling mediated drug tolerance
Studies done in non-small-cell lung cancer (NSCLC) cell lines with tyrosine kinase
inhibitors (TKIs), proved the existence of a surviving population of cells that survived
drug concentrations 100-fold above the IC50. Gene expression profiling of these persister
cells revealed KDM5A/Jarid1A and a histone H3K demethylase to be up-regulated. These
genes have functions spanning chromatin modification and the authors compared them to
persisting bacterial cells that survive antibiotic therapy. Perhaps the comparison is valid,
considering that the bacterial survivors were a result of stochastic gene modifications that
allowed the population subset to survive. Although, persistence in cancer cells could be
due to many individual single cell mechanisms [134].
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Cell-extrinsic mechanisms of establishment of minimal residual disease.
The profound effect of the tumour micro-environment during all stages of tumourigenesis
and therapy has been investigated for decades, so naturally, the effect of the tumour micro-
environment on the establishment of minimal residual disease has also been revealed to
a large extent. Micro-environmental factors like oxygenation, interstitial fluid pressure,
acidity and proximity to fibroblasts or immune cells vary greatly in the context of a large
solid tumour and as such may result in gradients in cell proliferation and more importantly
a variation in the efficacy of anticancer drugs[135]. More specifically, cancer cells or cells
within the tumour micro environment have been shown to secrete growth factors [136]
or tyrosine kinase ligands that then activate pathways mediating cell survival and drug
resistance of cancer cells[137].
The concept of cancer immunoediting [138] probably best describes the effect of the
immune system on the tumour micro-environment and growth, unraveling how cancer
cells use this to survive therapeutic intervention. The sequential phases of immune editing
include elimination followed by establishment of equilibrium and eventually escape. In the
elimination phase, tumour cells are destroyed by cytotoxic CD8+ T lymphocytes (CTLs)
by inducing tumour cell lysis [139]. Despite this efficient clean-up of transformed cells,
some rare cells survive in a dormant state [140]. The theory behind their survival rests on
the fact that they evade the immune system via molecular changes and this allows them
to lay dormant over a long period of time (equilibrium). As a consequence of constant
immune selection pressure on genetically unstable tumour cells, changes that favor growth
of the surviving tumour cells are eventually selected. These are no longer recognized by
the immune system and thus “escape” immunosurveillance.
Another crucial component of the micro-environment that effects tumour progression
is the vasculature. It provides the growing tumour mass with nutrients and oxygen and as
such can cause profound effects if it grows abnormally or does not penetrate the tumour
mass efficiently. Abnormal vasculature may result in a dynamic metabolic landscape for
cancer cells due to tumour patches where there is hypoxia and malnutrition. This kind of
“angiogenic dormancy” can prevent tumour growth [135]. Studies have shown that apart
from the diffusion of nutrients and gases, the clearance of acidic metabolites is also a
vital function of the vasculature [141]. Decreased clearance at distal tumour lobules that
are not vascularized efficiently can cause pH changes that in turn effect the activity of
anti-cancer drugs [142] aiding therapy evasion. Another cellular mechanism used by the
surviving population of cancer cells with regards to vasculature patterns and hypoxia, is
the activation of oxygen sensitive transcription factors – HIF1 and HIF2. These transcrip-
tional modulators activate multiple programs to combat apoptosis, including induction of
autophagy as the ultimate survival process before cell death [70].
Following this discussion of the many cell-intrinsic and cell-extrinsic mechanisms, used
by residual disease cells to persist at the site of tumour after therapy, it is probably
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not completely unreasonable to hypothesize that multiple of these mechanisms may be
employed by different cells in the same tumour. This variation could depend on factors
like the type of tumour, the location of the tumour and the micro-environment it grows in.
Encompassing this variability however, is one of the central mechanisms used by residual
cells to survive – tumour dormancy. All cells surviving initial insult therapy lay dormant
for a variable period (ranging from months to decades) of time before re-establishing
malignant disease [143][144] at the initial site or at a distant metastatic site.
Tumour dormancy is a phenomenon observed in clinical practices which refers to a
temporary halt in tumour progression, with a prolonged latency. This means, the patient
is rendered disease-free during the tumour dormancy period and complete remission (CR)
is coupled with absence of clinically detectable tumour recurrence[145]. The presence
of tumour dormancy in patients has been shown in many cases of breast cancer[143],
prostate cancer [144], melanoma renal cell carcinomas [146] and other tumour sub-types.
Recurrences in these patients are sometimes seen after decades of disease-free survival.
Tumour dormancy can be on a cellular level or more on a whole tumour mass scale. tu-
mour mass dormancy happens due to the factors that constrain tumour expansion despite
cell proliferation. The balance between cell division and apoptosis is achieved through
the conditions in the microenvironment, be it the lack of nutrients and oxygen or immune
system responses that efficiently eliminate the tumour cells [147]. The cellular dormancy,
on the other hand, is a true mitotic arrest in the tumour cells. Residual disease establish-
ment is quite possibly a combination of both these dormancy inducing processes. In this
project, I aim to explore the cellular dormancy mechanisms that cause residual disease so
as find ways to target the cellular reservoir of dormant cells that will revert to refractory
disease eventually.
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Rationale for targeting regressing tumours and the residual disease state
Unraveling so many mechanisms by which residual cells can survive leads to hypotheses
that targeting the establishment and persistence of residual cells may be the ultimate way
to cure cancer –eradication of all tumour cells capable of driving relapse. In the clinic,
targeting residual disease is a logical choice due to the following main reasons:
First, there is a reduction of tumour burden at this stage. This confers many advantages
to the treatment of residual disease, for example, a presumably smaller number of treat-
ment refractory clones persist at this point. This implies that there is a reduced likelihood
of sub clonal resistance to one or more therapeutics [148]. Reduced tumour burden also
weakens the actual cancer cells that have survived. They are fewer in number and less ef-
fective at remodelling microenvironments, reprogramming infiltrating hematopoietic cells
and inducing chemoprotective niches [149]. As a result, certain drugs may have greater
efficacy against MRD than against the same cancer at the time of clinical relapse.
Second, if the drugs for treating the residual cells are toxic and lead to many side effects
(as they commonly do), a patient treated for residual disease eradication at this stage has
a better chance of survival than for example in the relapse tumour stage, when the body
is under active tumor stress.
Despite these many mechanistic and practical reasons mentioned above, the most con-
vincing evidence that targeting residual disease may be the best option for pateints with
cancer, is the proof of principle published by researchers and technicians using neoadjuvant
therapy. Assuming the prevention of relapse, is a measurable surrogate for cure, patients
following resection of epithelial tumours and sarcomas, treated with adjuvant (and to some
extent neo-adjuvant) therapy intended to eradicate MRD achieve long-term disease-free
survival with the combination of surgery and adjuvant (or neoadjuvant) therapy than with
surgery alone [150] [151] [152] [153] [154] [155] [156]. Similarly, for haematological cancers
such as acute leukaemias or aggressive lymphomas, a single cycle of intensive chemother-
apy can induce complete remission , but virtually no patients are cured without additional
therapy to eradicate residual disease[157]. Additional therapy aimed at residual disease
in combination with targeted tumor therapy could thus have the potential to limit re-
lapse tumor prevalence and the concept of synthetic lethal interactions within tumour
cells could help us identify the most promising combinational therapies to achieve this
goal, as discussed in the following chapter.
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3.1.2 Synthetic Lethality
Synthetic lethality was discovered by fruit fly researchers in the early 20th century[158].
They discovered that, certain non-allelic genes were lethal only in combination, even
though the homozygous parents were perfectly viable. Synthetic lethality is thus de-
fined as an interaction that occurs between two genes when a perturbation (a mutation,
RNA interference knockdown or inhibition) that affects either gene alone is viable but the
perturbation of both genes simultaneously is lethal [159].
The question of why synthetic lethal interactions occur is probably best answered by
studying biological processes like evolution, developmental canalization (ability to pro-
duce the same phenotype regardless of genotype) and cancer (also other multifactorial
diseases)[160][161]. The need to maintain homeostasis in the face of diverse genetic and
environmental challenges in these processes, frequently leads to synthetic lethal interac-
tions. These interactions make the organism or process more genetically robust[162] [163].
Robustness is mostly provided by two well studied mechanisms of buffering:
1. Via non-homologous genes operating in the same cellular process or in back-up
pathways[164].
2. Via “capacitors” like heat shock proteins and chromatin regulators that can mask
the effects of many different mutations [165] [166].
Thus, cellular systems maintain homeostasis partly by ensuring that processes do not
depend on any single component, which could easily be perturbed by mutation or envi-
ronmental effects, setting the scene for synthetic lethal interactions[167].
Exploiting synthetic lethal interactions to identify new anticancer drug targets has been
pursued by researchers for over 20 years now [168]. In cancer cells, the process of ”oncogene
addiction” is well studied and exploited for therapy by targeting the oncogenes that the
cells get addicted to[169]. But although small-molecule and antibody-based inhibitors of
oncogenes have proved to be effective for some tumour genotypes, not all tumours have
targetable gain-of-function oncogenes, and therapeutic resistance is a common outcome.
However, these cancer cells got through a lot of genotoxic stresses and have been
shown by us in the lab and others, that they have distinct profiles from their wild type
counterparts[52][127]. This points to a ”re-wiring” process that could expose new ge-
netic vulnerabilities. Synthetic lethal interaction partners of cancer-associated molecular
changes – “non-oncogene addiction“ interactions – have therefore become of great value
for therapeutic opportunities [170].
The protein product of a gene that has a synthetic lethal interaction with a frequently
occurring tumour-specific somatic mutation would be an excellent anticancer drug tar-
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get, because a therapeutic that exploits the synthetic lethal interaction should result in
favourable therapeutic indices, in which only tumour cells that harbour the mutation
would be sensitive to the therapeutic (Figure 3.1) .
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Figure 3.1: Exploiting synthetic lethality for anti-cancer therapy
One of the early and possibly still the best examples of this kind of therapy is seen in
the case of DNA repair enzyme called PARP that was proved to be synthetic lethal with
DNA repair genes BRCA1 and BRCA2, mutations in which can cause breast and ovarian
cancer. tumours of patients carrying these mutations could be successfully treated using
a chemical PARP inhibitor with remarkably mild side effects [171] [172].
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3.2 Objectives
The main aim of this project was to better understand the molecular basis of residual
disease in mouse mammary carcinoma and gain insight into the apoptotic pathways acti-
vated in the regressing tumour mass as well as understand the senescence, growth arrest
and repolarization pathways activated in the residual cells. The goal was to understand
the survival mechanisms invoked by residual cells and target the key molecular players
involved in them. This would allow us to identifying potential synthetic lethal targets for
clearing residual disease.
To achieve this aim, we established the following objectives for this study:
1. Characterize the in vitro reductionist model of the TetO-MYC/ TetO-Neu/ MMTV-
rtTA organoids during tumour regression and analyze the kinetic transcriptome signature
during this process.
2. Characterize the analogous in vivo path to residual disease in TetO-MYC/ TetO-
Neu/ MMTV-rtTA mice with induced tumours and establish reproducible timelines for
tumour progression and regression both in-vitro and in-vivo
3. Employ an unbiased data analysis approach to identify genes specifically up-
regulated during regression to rescue surviving residual cells both in the reductionist in
vitro system and immune proficient mouse model. If successful, this objective extends to
testing the efficacy of inhibiting these targets using an appropriate experimental setup.
4. Perform live cell imaging of regressing tumours, in vitro, using Selective Plane
Illumination Microscopy (SPIM) in a more biased approach, to understand regression dy-
namics and draw inferences on potential survival mechanisms used by cells reintegrating
into the residual rims.
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3.3 Results
3.3.1 Characterization of minimal residual disease in vitro using pri-
mary organoids
The TetO-MYC/ TetO-Neu/ MMTV-rtTA mouse model, described in detail in the In-
troduction section of this report, was employed to obtain a correlate of minimal residual
disease in vitro.
3D matrigel cultures were established from single cells, isolated from the mammary
glands of adult TetO-MYC/ TetO-Neu/ MMTV-rtTA female mice. Subsequent to 4-7
days growth in embedded matrigel matrix, these single cells grow to resemble acinar-
looking, polarized structures with a central lumen (Figure3.2a, left panel). Continuing
on, these hollow acinar structures without any exposure to oncogenic proteins will be
referred to as the “Normal” or “Never Induced” acini. Owing to their resemblance in
structure and function to the basic ductal units of mammary glands, they are considered
the healthy mouse correlate of the healthy human breast morphology. The left panel in
Figure 3.2b shows this stage in an immunofluorescence staining of 3D cultures with the key
polarity markers : Alpha 6 integrin (ITGA6, shown in red) has a basal localization; Zonula
Occludens (ZO-1, shown in green) is apical, staining occludins at the tight junctions and
the Golgi matrix protein (GM-130, shown in magenta) is restricted to apical part of the
cell, marking the Golgi.
Upon introduction of doxycycline into the culture media, bright field microscopy shown
in Figure 3.2a, middle panel shows the establishment of a tumourigenic phenotype after
five days of doxycycline exposure. The activation of oncogenes c-MYC and Neu in the
hollow acinar cells results in high proliferation rates and crowding of cells in the lumen.
Subsequent breaking of polarized epithelium phenotype results in filling of the lumen and
expansion of these acini to several times their original dimensions. Several lobules are
formed and the growth is prolific, accompanied by a higher apoptosis rate, as is commonly
observed in proliferating tumour cells. This tumourigenic acinar state is referred to as “5
Days ON DOX” and is the correlate of “Tumour” in human disease. The immunofluo-
rescence staining of 3D cultures at this this stage vary greatly from what is seen in the
“never induced” state as seen in the middle panel of Figure 3.2b.
Owing to the principle of oncogene induction discussed earlier, withdrawal of doxy-
cycline from the media results in rapid death and lumen clearing of the “tumour” acini.
Figure 3.2a, right panel shows the resulting acinar phenotype “7 Days OFF DOX”. De-
spite oncogenic exposure, the cells remaining in the reintegrated rims at this stage could
be compared to the human correlate of “Minimal Residual Disease” and will be alluded
to as such in this study. As shown by the IF staining of 3D cultures at this stage, residual
disease structures are phenotypically very similar to “never induced” state as seen in the
Figure 3.2b, right panel.
The advantageous use of 3D cultures established from primary murine mammary ep-
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Figure 3.2: Representative (a) Bright field microscopy images (Scale bar, 100 µm) and
(b) Immunofluorescence staining images (Scale bar, 25 µm) of fixed 3D gels with TetO-
Myc/TetO-Neu/MMTV-rtTA organoid culture. Left panels show the normal mammary
acini grown from primary cells harvested from the mice. Middle panels show the tumour
organoids that develop post induction with doxycycline for 5 days in culture. Right panels
show the regressed tumours after 7 days of doxycycline withdrawal. Polarity markers
include alpha-6-Integrin (red), GM-130 Golgi marker (magenta), ZO-1 (green) and DAPI
nuclear stain (blue).
ithelial cells allowed close monitoring of the c-MYC and Neu expressing tumour phenotype.
This included observing initiation and regression closely under the microscope and estab-
lishing the timeline for oncogene activation and dependence during tumour formation and
similarly “oncogenic shock” upon acute onco-protein inactivation. Immunofluorescence
staining experiments utilizing 3D gels harvested and fixed at multiple time points during
the kinetic processes of apoptosis, repolarization and establishment of residual rims during
the tumour regression phase have shed much light on the molecular characteristics of these
cells over the seven days of in vitro regression. After 5 days of induction with doxycycline
media, oncogenic protein degrades within 12 hours of de-induction. The inner tumour
mass undergoes apoptosis rapidly and re-establishment of the polarized epithelial rim is
seen within 72 hours. The surviving rim enlarges and apoptosis is near complete by day
7 after removal of doxycycline from the media.
Detailed characterization of the regression phase after de-induction of oncogenes has
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allowed for better characterization of the cellular events that occur in this phase: onco-
protein depletion (6-8 hours after de-induction), apoptosis (as early as 8 hours after de-
induction), clearing of the tumour core (24-36 hours after de-induction), re-polarization of
epithelial cells around a central lumen (36-72 hours after de-induction) and establishment
of a dormant residual rim (by 7 days after de-induction). Figure 3.3 shows representative
IF stains demonstrating these findings.
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Figure 3.3: Representative Immunofluorescence staining images of fixed 3D gels with
TetO-Myc/TetO-Neu/MMTV-rtTA organoids harvested during tumour regression(upon
doxycycline withdrawal). Left panels show polarity staining with markers including
alpha-6-Integrin (red), GM-130 golgi marker (magenta), ZO-1 (green) and DAPI nuclear
stain(blue). Right panels show cell death with the help of the cleaved Caspase-3 stain
(green). E-cadherin(red) is used as membrane marker and DAPI is the nuclear stain(blue).
Scale bar, 50 µm.
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3.3.2 RNA sequencing analysis of in vitro organoids during the estab-
lishment of MRD
Equipped with the aforementioned findings, the objective to unravel the kinetic transcrip-
tome during tumour regression and minimal residual disease establishment was furthered,
in that we could now ascertain the hallmark timepoints at which “transcriptomic snap-
shots” would be worth exploring in these in vitro cultures. We established organoid
cultures from single cells isolated from the mammary glands of four different adult TetO-
MYC/ TetO-Neu/ MMTV-rtTA female mice, induced and then de-induced oncogenic
expression in the resulting mammary acini and collected RNA samples at the hallmark
points on the regression time-scale (Figure 3.4).
Cdh1 (E-cadherin membrane marker) and c-MYC immunofluorescence staining per-
formed early during tumour induction with doxycycline, revealed that the expression of
oncogenes is relatively quick, already visible with c-MYC co-localization in some acinar
cells at the 4 hours ON DOX timepoint (Figure 3.4, right upper panel). To capture the
very early tumour signaling networks, we included 1, 2 and 4 hours ON DOX timepoints
into the scheme. Similarly, Cdh1 (E-cadherin membrane marker) and c-MYC immunoflu-
orescence staining at early timepoints after doxycycline depletion from the culture media,
showed that the oncoprotein had a very short half-life and the protein was no longer
visible as early as 8 hours OFF DOX(Figure 3.4, right middle panel). Coupled with a
Cdh1 (E-cadherin membrane marker) and cleaved Casp3 (Caspase-3 apoptotic marker)
immunofluorescence stain at the same time point (Figure 3.4, right lower panels), we see
that Caspase-3 has already been cleaved in some cells implying that the depletion of the
oncogene and decision to apoptose has already been taken at this point. To gain as much
insight into the transcriptomic signatures during this important “survive-vs.-apoptose”
stage, we included 4, 6, 8, 10 and 12 hours OFF DOX timepoints into the scheme. Be-
cause all the transcriptomic snap shots would be compared to the “Never Induced” tran-
scriptomic snap shot, the evolution of the transcriptomic signature of the normal acini
were taken into account. Cultures grown without doxycycline alongside other cultures on
doxycycline were collected at the 5 days ON DOX timepoint and similarly after 7 days
at the 7 Day OFF DOX timepoint. I performed immunofluorescence staining in parallel
3D matrigel cultures for oncogenic, apoptotic and polarity markers to ensure the organoid
characteristics did not vary too much from the expected. RNA samples were sequenced at
the Genomics Core Facility at EMBL Heidelberg using NGS HiSeq protocol – 75bp read
length, 30x coverage.
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Figure 3.4: Hallmark time points during tumour progression (purple) and tumour regres-
sion (green). RNA was collected from in vitro matrigel cultures at these timepoints and
RNA sequencing was performed to unravel the dynamic transcriptome. Scale bar, 50 µm.
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Principal Component Analysis (PCA) plotting of data points across the time series and
subsequent bioinformatics analysis was performed by Katharina Zirngibl from the Patil
Group at EMBL, Heidelberg. The first and the second principal components accounted
for 38% and 22% of the variance, respectively. It is apparent (Figure 3.5) that the “7
days OFF DOX” timepoint (represented by the darkest green dots in the green regression
kinetic arrow) indeed had a distinctive transcriptomic profile that distinguished it from
both the “5 days ON DOX” (represented by the darkest purple dots in the purple regression
kinetic arrow) and “Never Induced” (shown in gray) timepoints. This clearly indicates
that although the residual disease stage is phenotypically similar to the normal acini as
seen in the staining experiments, there is, in reality, a significant difference between them
on a transcriptomic level. These findings correlate with data published formerly by the
lab showing a distinct transcriptomic profile between “Never Induced and “7 days OFF
DOX” regressed acini on microarray chips. The residual disease substrate in this study
was also found to have an increased lipid metabolism and elevation of ROS species [52].
DeSeq2 expression analysis showed that over 5300 genes were significantly dysregulated
along the tumour progression and regression time course (compared to never induced
control, q value0,05), with a false discovery rate (FDR) of 1%. This is far too large
a number of genes to allow untangling of network connections using standard GO (Gene
Ontology) enrichment analysis. It was therefore decided to perform clustering of the genes
based on their expression trajectories along the time course.
Clustering would proved to have a twofold advantage :
1. Provide information regarding the broad gene expression trajectories during onco-
genesis/regression and discussion on which trajectories might belong to potential synthetic
lethal targets.
2. Serve as guidelines for classifying genes into fewer clusters for efficient network
analysis.
Clustering of the differentially regulated genes (over 5000) across the time series using
the GP Clust algorithm yielded 75 unique clusters (Figure 3.6). Each tiny graph in the
Figure 3.6 represents the average gene expression trajectory of a subset of genes. The
midpoint of the Y axis (at the marking ‘10’) indicates the point of de-induction along the
time course. Since the induction was performed for 5 days and de-induction for 7 days,
the gene expression trajectories have been normalized to fit an equidistant axis. The gene
expression levels all start at 0 (represented by the X axis) at the start and then either
increase or decrease. An inflection point normally occurs at the center (at the timepoint
when the organoids were de-induced) and not all gene expression values return to baseline.
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In Figure 3.7, the grey clusters on the left represent gene expression clusters that seem
to be upregulated (top) or downregulated (bottom) during tumour induction and then
return to normal along the course of regression. Conversely, the other four colorful clusters
in Figure 3.7 represent gene expression profiles that seem to be up-regulated temporarily or
permanently in varying intensities and peaks during tumour regression. Closer inspection
of the gene cluster trajectories is informative, therefore, in hypothesizing the gene clusters
that are simply a consequence of oncogene activation and addiction from the gene clusters
that seems to be upregulated during the establishment of minimal residual disease and
could therefore be potential synthetic lethal targets.
The clustering of over 5000 differentially regulated genes into 75 unique clusters based
on their expression trajectory, paved the path for us to manually curate the interesting
trajectory clusters and has helped us classify interesting trajectories into 5 broad clusters:
1. Sustained targets – upregulated consistently during regression up to residual disease
state
2. Early responders – upregulated early during regression before apoptosis decisions
are made (up to 8 hours after de-induction)
3. Intermediate responders – upregulated after apoptosis decisions are made to poten-
tially salvage residual cells/aid in tissue rearrangement to increase survival (12-24 hours
after de-induction)
4. Late targets – upregulated during re-polarization of epithelial cells into residual rim
(36 hours after de-induction onwards)
5. Shoulder trajectories – upregulated in tumours and continued sustained expression
during regression (at least up to 34 hours after de-induction)
To better understand the gene networks linked with the expression of oncogenes, gene
trajectories like the grey ones on Figure 3.7 were classified into “Expected Up” or “Ex-
pected Down” clusters. Genes in the “Expected Up” cluster seem to be upregulated during
tumour induction and then return to normal along the course of regression. Genes in the
“Expected Down” cluster, conversely, seem to be downregulated during tumour induction
and then return to normal along the course of regression.
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Figure 3.5: PCA plot for RNA Sequencing data of samples collected at hallmark timepoints
during tumour progression and regression (See Figure 3.4). Every dot along the arrows
is a data point for a biological replicate for the particular time point (arrows and points
colored purple for tumour progression, green for tumour regression and grey for never
induced controls). In-lay images show immunofluoresence staining for polarity markers at
the 3 endpoints. Scale bar, 50 µm.
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Figure 3.6: Genes found to be significantly deregulated along the time course shown in
Figure 3.5, with a false discovery rate (FDR) of 1%, were clustered across the time series
using the GP Clust algorithm to yield the 75 unique clusters shown in this figure.
The genes (number indicated in the box on the right-hand corner of each graph in
Figure 3.6), that belonged to the clusters with trajectories that looked similar to the
selected seven interesting trajectories, were pooled into manually curated clusters. Further,
to prevent loss of gene targets that did not meet stringent quality criteria but show similar
expression trajectories over the time course, we developed a correlation analysis algorithm.
Only the trajectories from the five potentially “synthetic-lethal” clusters (Figure 3.8 a)
were used to pull out other genes with similar trajectories from the whole data-set (Figure
3.8 b). Stringent filtering on fold change and significance of gene expression has yielded
a total of 473 potential synthetic lethal targets among these 5 interesting trajectories.
Including the “Expected Up” and “Expected Down” clusters the number of genes totals
1796 (Table 3.1).
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Figure 3.7: Example gene cluster trajectories from the 75 unique clusters (see Figure
3.6). Grey gene trajectories show gene expression deregulated due to oncogene expression.
This aberrant expression seems to return to normal upon oncogene de-induction. Colored
trajectories show genes with aberrant activity before and/or after oncogene withdrawal
that are hypothesized to help residual disease cells survive tumour regression. Time units
are normalized for graphical representation and grey lines at position 10 in each graph
show the point of oncogene de-induction.
Collaboration with Matt Rogon, Center for Biomolecular Network Analysis, EMBL,
Heidelberg was established so as to perform Gene Ontology Enrichment analysis of these
1796 genes in 7 manually curated clusters. Enriched GO terms for each of the 5 potentially
synthetic lethal clusters is shown in Figures 5.3, 5.4, 5.5, 5.6 and 5.7. A combined multi-
cluster gene enrichment analysis on all these potentially synthetic lethal gene clusters
is shown in Figure 3.9. The pathway enrichment information from the five potentially
synthetic lethal clusters – individually and in comparison – allowed us to narrow the list
of molecular players vital to establishment of residual rims.
This was done in a two-step process: first, we manually picked interesting GO terms
that seemed to be novel yet logical in the residual disease establishment landscape. These
included GO terms shown in Table 3.2
Next, we mapped each of these networks based on protein-protein interaction databases.
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Curated Cluster FDR Clustering Correlation Analysis Total
Expected-Up 1087
Expected-Down 236
Sustained Target 18 109
Early Response Target 33 9
Late Response Target 11 86
Intermediate Response Target 58 94
Shoulder Target 31 24
1796
Table 3.1: Gene numbers and sources for manually curated and potentially synthetic lethal
clusters that were used for gene enrichment and network analysis.
GO Term identifier GO Term
GO:0002819 Regulation of adaptive immune response
GO:0098742 Cell-cell adhesion via plasma-membrane adhesion molecules
GO:0002009 Morphogenesis of an epithelium
GO:0001213 Formation of the cornified envelope
GO:0031663 Lipopolysaccharide-mediated signaling pathway
GO:0017017 MAP kinase tyrosine/serine/threonine phosphatase activity
GO:0000097 Downregulation of ERBB4 signaling
GO:0000618 Oxidative Stress Induced Senescence
GO:0008593 Regulation of Notch signaling pathway
GO:0000571 FAS pathway and Stress induction of HSP regulation
Table 3.2: GO Terms enriched in the five potentially synthetic lethal clusters manually
curated from RNA Seq analysis.
As shown in Figures 5.8 to 5.17, we mapped the network proteins for each pathway and
further expanded the net by including the first neighbor proteins of all the proteins in
the particular network. First neighbors are proteins that have been shown, experimen-
tally and/or theoretically, to interact in a cellular environment. Filtering the GO-term
-protein + first-neighbor network based on availability of drugs for inhibition of gene/
protein target further helped in narrowing the list of potential synthetic lethal targets to
interfere with minimal residual disease. Further, manual filtering for biological relevance
was postulated to provide a comprehensive list of targets for validation.
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Figure 3.8: (a)Five broad, interesting gene expression trajectories that could belong to
potential synthetic lethal targets – picked manually based on biological criteria. (b) Cor-
relation analysis algorithm used to pull out genes from the whole RNA Seq data set to
enrich single gene trajectory clusters in (a)
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Figure 3.9: Schematic representation of enriched GO terms within the genes in clusters
with potential synthetic lethal trajectories. GO term groups that are connected with
grey lines and shown in the same color represent grouping based on broader a Molecular
Function(MF) analysis.74
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3.3.3 Characterization of minimal residual disease in vivo in mice
Establishing a pure correlate of minimal residual disease using mouse mammary glands
and organoid cultures has proved useful in elucidating mechanisms of tumour regression
as seen in the previous findings of the lab [52] and the findings so far in this report.
However, although the 3D culture system is clean and synchronous it provides a rather
reductionist approach, owing to the fact that key cell compartments of the breast tissue are
missing from this system: fat cells, myoepithelial cells, fibroblasts and most importantly,
a functioning immune system. Without the complexity encountered in living organisms,
it was deemed important to validate our in vitro findings in an in vivo context, using
mouse experimentation. Before we started to explore certain synthetic lethal targets and
the effect of their inhibitors in vitro, we wanted to know that these targets were indeed
upregulated in mice with full organ morphology and a proficient immune environment.
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Figure 3.10: Immunohistochemistry (IHC) staining of mouse mammary tissue sections
during the regression of mammary tumours upon withdrawal of doxycycline from the
diet of TetO-MYC/ TetO-Neu/ MMTV-rtTA mice. (a) IHC stains for Ki67 proliferative
marker and (b) cleaved Casp3 apoptotic marker in mammary glands at the indicated
times during tumour regression. Counter stained with haematoxylin. Scale bar, 50 µm.
The first step was naturally characterizing the inducible tumour model in vivo. TetO-
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MYC/ TetO-Neu/ MMTV-rtTA adult female mice (between 8-10 weeks old) were ad-
ministered food with doxycycline so that they developed tumours. Palpable tumours were
observed within 5-6 weeks (median time to tumour = 38 days) when oncogenes are induced
in their mammary glands by administration of food with doxycycline. Tumours were al-
lowed to grow until the tumour burden was considered too high (any tumour lobule is
more than 2 cm in diameter) and then the mice were switched to normal food without
doxycycline. Thereafter, rapid tumour regression follows, wherein tumours are no longer
palpable as early as 2-3 weeks after removal of doxycycline from the animal diet. However,
upon sacrificing and dissecting mice 2-3 weeks OFF DOX we observed micro tumours and
regressing nodules in the mammary glands. Consequently, the animals were allowed to
regress for longer to allow complete regression. IHC staining for apoptosis and prolifera-
tive markers was performed at various timepoints during in vivo regression (Figure 3.10)
and 9 weeks OFF DOX was ascertained as the “residual disease” state. Animals showed
continued apoptosis in their mammary gland tissue, until 6 weeks after removal of doxy-
cycline from the animal diet. Analogous to the in vitro regression, IHC stains early after
doxycycline withdrawal from the animal diet, showed massive cell death and depletion of
oncogene within 48 hours. This contributed to deciding the hallmark timepoints during
in vivo mammary tumour regression in this mouse model.
At the hallmark time points shown in Figure 3.11, tissue samples were collected from
3 mice (biological replicates) per time point. An age matched control was also harvested
with each tumour/regressing tumour mouse. This was frequently a wild type or unin-
ducible genotype sibling. Typical harvest from these mice included:
1. Fixed tissue for paraffin embedding and histology
2. Frozen tissue for DNA, RNA, protein extraction
3. Estrous smears to control for estrous cycle effects on gene expression/protein levels
RNA samples from mouse mammary tissue were run on microarray chips for gene
expression profiling. Analysis of the microarray data and differentially regulated genes
and pathways compared to control mice was performed using the Transcriptome Analysis
Console (TAC) 4.0 software. Principal Component Analysis (PCA) plotting of this mi-
croarray dataset (Figure 3.11) follows the trend observed in the in vitro dataset with the
residual disease correlate clustering distinctly from the control samples despite phenotypic
similarity in tissue morphology.
76
Quest for the Achilles’ heel in breast cancer residual disease
4 days
 OFF DOX
1 day
 OFF DOX
2 weeks 
OFF DOX
1 week
 OFF DOX
 4 weeks 
OFF DOX
Control 
(Never ON DOX)
Tumour 
(6-8 weeks ON DOX)
Residual Disease
8- 9 weeks OFF DOX)
Figure 3.11: PCA analysis plot for micro array data from samples collected at hallmark
time points during tumour regression in mice. Each dot on the plot represents a biological
replicate and the stage of harvest is color coded with the schematic bubbles.
Now equipped with the gene expression changes in the mouse model with organismal
complexity, we performed a manual overlay of gene enrichment analysis for both in vivo
and in vitro datasets. This yielded the following interesting subgroups of pathways that
seem to be altered both in reductionist 3D cultures and immune proficient mice during
tumour regression:
(a) Focal Adhesion PI3K- AKT-mTOR Sinalling Pathway
(b) MAPK Signalling (specifically: c-Jun Kinase/Stress-activated Pathway)
(c) TNF-alpha and NF-κB signalling pathway
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(d) Tgf-Beta Signalling pathway
(e) DNA damage response (ATM dependent)
(f) Apoptosis pathways.
Key molecular players from these pathways were selected for validation, including c-
Jun, BCl-6 and CCl5.
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3.3.4 Validation of selected targets for synthetic lethality during estab-
lishment of MRD
Key molecular players that were identified and hypothesized to be involved in the estab-
lishment of residual disease— c-Jun, BCl-6, CCL5 — were taken forward for validation.
These targets were identified from network analysis on in vivo and in vitro transcriptomic
datasets and so the logical next level of validation would be the protein level.
Using IHC and immunofluorescence staining, c-Jun protein was shown to be enriched
significantly in the MRD correlate of the in vitro 3D cultures (Figure 3.12a) as well as the
tissue sections of the regressed mammary glands harvested from mice (Figure 3.12b). As
indicated in the graphs in Figure 3.12a & b, c-Jun was upregulated on the transcriptomic
level. It is an important transcription factor involved in numerous cell activities, such
as proliferation, apoptosis, survival, tumourigenesis and tissue morphogenesis[173]. It
has already been shown to be relevant in the human breast cancer landscape because it
cooperates with NF-B to prevent apoptosis induced by TNF [174]. Protein validation of
c-Jun warranted further functional validation of this target. We aimed to functionally
validate c-Jun first in the in vitro context by testing the effect of its inhibition on the
establishment of residual disease rims.
Sylwia Gawrzak in the group collaborated with me to adapt our primary murine mam-
mary cultures to her inhibitor screening pipeline using 3D cultures, high throughput imag-
ing and cell viability and toxicity assays. Inhibitors of potential synthetic lethal targets
were to be tested in in vitro cultures in the context of combinatorial treatment — inhibitors
were to be added during removal of doxycycline (“ideal therapy”). The hypothesis was,
that if the cells surviving therapy and reintegrating to form residual disease rims were
dependent on the synthetic lethal target, then an inhibitor for the target applied during
oncogene withdrawal would reduce the number of cells surviving and limit the reservoir
of cells establishing the minimal residual disease correlate. As such, we expected to see
reduced cell viability and increased cell death in regressing organoids that were taken off
doxycycline (“ideal therapy”) along with an inhibitor against the synthetic lethal target
as compared to simply organoids regressing because of doxycycline withdrawal.
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Figure 3.12: (a) Gene expression profile for c-jun in 3D cultures undergoing tumour
regression are shown in the blue graph. Y-axis indicates the log2 Foldchange values of
gene expression at each timepoint as compared to the Never Induced timepoint. The
IF staining panels below show protein localization of c-jun (green) in 3D acinar cultures
at Never Induced(control), 5 day ON DOX (Tumour) and 7 days OFF DOX (residual
disease) timepoints. Cdh1 (E-cadherin) used as membrane marker in red. (b) Gene
expression profile for c-jun in mammary tissue of mice undergoing tumour regression are
shown in the orange graph. Y-axis indicates the log2Foldchange values of gene expression
at each timepoint as compared to the Control. The IHC staining panels below show
protein localization of c-jun in mammary tissue sections of control mice , tumour mice
and mice harvested after 9 weeks OFF DOX (residual disease stage). Counterstained with
haematoxylin. Scale bar, 50 µm.
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CellTox™ Green Cytotoxicity Assay
Fluorescence Read-out
CellTiter-Glo® Luminescent Cell Viability Assay
Luminescence Read-out
ScanR automated imaging
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oncogenes
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Figure 3.13: Experimental design for the in vitro target validation. To test the synthetic
lethality of identified genes, their inhibitors would be supplemented in the culture media
starting from the point of doxycycline withdrawal. Optical, Luminescence and Fluores-
cence readouts were incorporated to evaluate phenotype variation, cell viability and cell
death.
To test this hypothesis, we adapted our 3D culture method to mini 3D gels (5ul) in
a 96 well format (experimental design summarized in Figure 3.13). This format allows
for experimental reproducibility and reduced variability – because one can test varying
concentrations of the inhibitors on the same plate with the appropriate controls and enough
technical replicates to perform statistical testing. The 96- well mini-gel format also allowed
for:
(a) Optical readout via high throughput ScanR imaging
This facilitated following whole gels over the time course visually to demarcate phe-
notypic changes.
(b) Cell Viability read-out using CellTiter-Glo R© Luminescent Assay
This outputs a well-wide viability parameter that is ATP dependent and can be used
to compare metabolically active cells in each well using a luminescence read-out.
(c) Cytotoxicity and Cell Death readout via CellToxTM Green Fluorescence Assay This
outputs a well-wide cell toxicity parameter that is biomarker dependent and can be used
to compare apoptosis in each well using a fluorescence read-out.
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Table 3.3 shows the list of inhibitors tested using this pipeline on 3D cultures grown
from TetO-MYC/ TetO-Neu/ MMTV-rtTA mouse mammry glands. We tested inhibitors
for c-Jun namely Tanshinone IIA and JNK inhibitor SP600125; BCL-6 namely FX-1 and
79-6 inhibitor and two targets that form integral parts of the NF-κB cascade, CCL5
with it’s antagonist Maraviroc and the IKK2 kinase with the IKK2 -IV and IKK2-VIII
inhibitors.
Inhibitor tested Inhibitor target Concentration range(µM) tested
Tanshinone IIA (AP-1 inhibitor) c-Jun 0.1 - 80
SP600125(JNK inhibitor) c-Jun 0.02 - 80
FX-1 Inhibitor Bcl6 15.6 - 4000
79-6 Inhibitor Bcl6 1.95 - 1000
IKK2 Inhibitor IV Ikbkb 3.125 - 50
IKK2 Inhibitor VIII Ikbkb 0.39 - 100
Maraviroc CCL5 antagonist 6.25 - 100
Table 3.3: Inhibitor list tested for synthetic lethality in regressing mammary matrigel
cultures using the pipeline outlined in 3.13.
Bcl6 is a strong transcriptional repressor implicated in B-cell lymphomas and other
solid cancers. It has recently been implicated to have a role in human breast cancers using
cell line models and bioinformatic analysis [175]. It has also been shown that higher BCl-
6 expression reduces relapse free survival in HER2+ patients (Online KM plotter[176]).
In our model system, commonly repressed proteins like the ones controlling DNA dam-
age sensing (eg: Atr, Chek1, Trp53, Cdkn2a) and proliferation checkpoints (eg: Cdkn1a,
Cdkn1b, Cdkn2b, Pten) are found to be downregulated during tumour regression. These
are all known to be repressed by Bcl6. In addition, Bcl6 upregulation could be validated
on a protein level in the 3D cultures where it was found to be enriched in regressed rims as
compared to never induced acini (Figure 3.14). Combined with the elevated transcriptomic
signatures from the in vitro and in vivo experiments, it qualified for functional validation
with the inhibitor screening pipeline.
Similarly, targets from the NF-κB cascade were also tested for synthetic lethality using
this pipeline. The NF-κB complex proteins such as Rel and Relb were shown to be
upregulated in vitro and in vivo during regression. Previous literature suggests that
TNFα-induced NF-κB activation induces transcription and expression of genes encoding
anti-apoptotic factors Birc2, Birc3 and Bcl2 homologue Bcl2l1 [174]. Transcriptome levels
of all these anti-apoptotic factors along with the Tnf RNA are also upregulated in the
minimal residual disease correlates in our system (See schematic in Figure 3.15).
As hypothesized earlier, inhibiting a true synthetic lethal target is expected to have
a pronounced deleterious effect on regressing tumours. Controlling for inhibitor toxicity
was performed using a dose curve method of experimental design and by applying the
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inhibitor on Never Induced acini in gels grown on the same plate. As such, upon addition
of a synthetic lethal target inhibitor, we would expect the regressing tumour acini to show
decreased viability and at the same time we would expect no effect on the Never induced
acini. A target cannot be synthetic lethal if it’s inhibitor, at a given concentration, is less
toxic towards regressing organoids in comparison with normal mammary acini.
Figures 3.16 and 3.17 show the readouts from the CellTiter-Glo R© Luminescent Assay
(viability) and CellToxTM Green Fluorescence Assay (cell death) for two c-Jun inhibitors
– Tanshinone IIA and JNK inhibitor SP600125. Both experimental readouts for both
inhibitors indicate that although the inhibitor severely reduces residual disease viability
at higher doses, this correlate is far more refractory than normal never induced mammary
organoids. Similar results were obtained during the testing of all the inhibitors mentioned
in Table 3.3 ( See Supplementary Figures 5.18, 5.19, 5.20 and 5.21).
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Figure 3.14: Gene expression profile for Bcl6 in 3D cultures undergoing tumour regression
are shown in the blue graph. Gene expression profile for Bcl6 in mammary tissue of mice
undergoing tumour regression are shown in the orange graph. Y-axis indicates the log2
Foldchange values of gene expression at each timepoint as compared to the Never Induced
timepoint or Control mice. IF staining panels show protein localization of Bcl6 (green)
in 3D acinar cultures at Never Induced (Control), 5 day ON DOX (Tumour) and 7 days
OFF DOX (residual disease) timepoints. Cdh1 (E-cadherin) used as membrane marker in
red. Scale bar, 50 µm.
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Figure 3.15: Schematic representation of the molecular players in the NF-κB cascade and
their feedback signalling loop with CCR5 receptor anti-apoptic signalling during in vitro
breast cancer regression. Molecular targets highlighted in red were up-regulated along the
regression transcriptome of our 3D culture system.
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Figure 3.16: Cell Viability and Cell Death readouts from synthetic lethality testing of
inhibitor Tanshinone II A against the identified traget c-Jun. Upper left graph shows the
readout from the CellTiter-Glo R© Luminescent Assay. Cell viability readouts for the 5
doses of Tanshinone IIA tested and normalized against the control are shown. Derived
from this graph is the upper right graph depicting the Cell Viability response curve. IC50
values for Tanshinone IIA in the Cell Viability response curve are 0.0029 mM for Never
Induced and 0.025 mM for Regressed cultures. Lower left graph shows the readout from the
CellToxTM Green Fluorescence Assay. Cell death readouts for the 5 doses of Tanshinone
IIA tested and normalized against the control are shown. Derived from this graph is the
lower right graph depicting the Cell Death response curve. IC50 values for Tanshinone IIA
in the Cell Death response curve are 0.0063 mM for Never Induced and 0.0265 mM for
Regressed cultures.
86
Quest for the Achilles’ heel in breast cancer residual disease
SP600125 Dose (M)
Co
nt
ro
l
0,
00
03
12
5
0,
00
12
5
0,
00
5
0,
02
0,
08
0.0
0.5
1.0
1.5
2.0
Co
nt
ro
l
0,
00
03
12
5
0,
00
12
5
0,
00
5
0,
02
0,
08
0
1
2
3
4
5
N
o
rm
al
iz
ed
 F
lu
o
re
sc
en
ce
SP600125 Dose (M)
-4 -3 -2 -1
0
50
100
150
V
ia
b
ili
ty
SP600125 Dose (M)
-4 -3 -2 -1
0
50
100
150
SP600125 Dose (M)
C
el
l D
ea
th
Never Induced
Regressed
Cell Titer Glo Assay
N
o
rm
al
iz
ed
R
el
at
iv
e 
L
u
m
in
es
ce
n
ce
 U
n
it
s
Never Induced
Regressed
Cell Viability- Response Curve
Cell Death - Response CurveCell Tox Assay
Figure 3.17: Cell Viability and Cell Death readouts from synthetic lethality testing of
inhibitor JNK Inhibitor SP600125 against the identified traget c-Jun. Upper left graph
shows the readout from the CellTiter-Glo R© Luminescent Assay. Cell viability readouts
for the 5 doses of JNK Inhibitor SP600125 tested and normalized against the control are
shown. Derived from this graph is the upper right graph depicting the Cell Viability
response curve. IC50 values for JNK Inhibitor SP600125 in the Cell Viability response
curve are 0.011 mM for Never Induced and 0.023 mM for Regressed cultures. Lower
left graph shows the readout from the CellToxTM Green Fluorescence Assay. Cell death
readouts for the 5 doses of JNK Inhibitor SP600125 tested and normalized against the
control are shown. Derived from this graph is the lower right graph depicting the Cell
Death response curve. IC50 values for JNK Inhibitor SP600125 in the Cell Death response
curve are 0.024 mM for Never Induced and 0.0246 mM for Regressed cultures.
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3.3.5 Imaging tumour organoid regression using light sheet microscopy
The primary focus of this study was to identify key molecular players in minimal residual
disease of breast cancer and the transcriptomic method described so far is an unbiased
approach to elucidate the mechanisms of establishment of minimal residual disease using
gene expression analysis (RNA Seq). In a more biased approach, we aimed to image the
special dynamics during regression to analyze mechanisms of survival of residual disease
cells in our 3D culture system.
To better understand the spatio-temporal dynamics of regressing tumours and visualize
the establishment of a minimal residual disease correlate, we exploited the 3D culture
method combined with the inducible TetO-MYC/ TetO-Neu/ MMTV-rtTA mouse model.
The reporter protein H2B mCherry was bred into the mouse line to fluorescently mark
the nuclei for imaging –to image regression in vitro. SPIM microscopy was ascertained
to be the most adept technique for this objective because it facilitates rapid live cell
imaging, with low photo-toxicity, greater penetration depths and low scattering owing to
illumination with a light sheet instead of a point source.
a.
b.
0:0 hrs 1:0 hrs 2:0 hrs 3:0 hrs 4:0 hrs
0:0 hrs 1:0 hrs 2:0 hrs 3:0 hrs 4:0 hrs
Figure 3.18: tumour organoids recorded at the In-Vi SPIM (Luxendo) for short periods
to test phototoxicity. (a) shows image acquisition with a z-step size of 0.5 µm, while (b)
shows image acquisition with a z-step size of 1 µm. Time stamps on the upper left corner
of panel images show times since the start of image acquisition at 10-minute intervals.
H2B-mCherry fluorescence in cells shown in grey. Scalebar, 10 µm.
However, one of disadvantages of this alternate optical arrangement- illumination with
a light sheet perpendicular to detection – is that SPIM microscopes often require spe-
cial sample mounting for imaging. Mounting procedures are sometimes incompatible with
optimal growth conditions for the 3D mammary epithelial cell cultures and must be estab-
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lished differently. For example, during my efforts to image mouse mammary acini with the
Mu-Vi SPIM (Multi-view SPIM), growth seemed to be impaired due to lack of diffusion
of nutrients with the media because the 3D cultures had to be seeded in 1mm diameter
FEP tubes. Similarly, I also experienced sample mounting incompatibility with the Leica
SP8 Confocal-SPIM for our 3D system. To suit the mounting needs of the SP8 SPIM, we
seeded matrigel cultures on 2 mm wide FEP strips and mounted them at an elevation to
allow the light sheet formation through the sample. Although we could image a few movies
on this system, the gel cultures were increasingly unstable over time and we experienced
frequent sample drift. Another disadvantage of this system was the inability to image at
multiple positions in the gel culture efficiently. However, the InVi SPIM made by Luxendo
was eventually shown to be ideal for our sample as detailed in the previous project in this
thesis.
Imaging on the InVi SPIM set up was optimized to reduce phototoxicity and so that the
imaging conditions would not affect cellular fates. In Figure 3.18, the upper panel shows a
movie recorded at the InVi SPIM over 4 hours, every 10 mins, with 0.5 µm z-step size. The
panels, as they progress from left to right, show bleaching of the fluorophore and eventual
phototoxicity in the sample. The lower panel of Figure 3.18 shows a similar recording
of organoid growth wherein the parameters were optimized to prevent photobleaching:
laser powers of 13.1 microWatts for the 488 nm laser and 36.4 microWatts for the 594
nm laser, 100 millisecond exposure time per frame, 1m z-spacing between frames and 10-
minute imaging intervals. A series of optimization experiments, involving different laser
powers, exposure times and z-step sizes yielded these parameters to be optimal for long
term imaging (96-120 hours) without photo-bleaching or photo-toxic effects on growth.
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Figure 3.19: Tumour regression recorded at the In-Vi SPIM (Luxendo) with manual track-
ing . Blue tracking dot marks a cell that exhibited movement to the surviving rim during
apoptosis of the core. Time stamps on the upper left corner of panel images show times
since doxycycline withdrawal from the 3D culture media. H2B-mCherry fluorescence in
cells shown in grey. Scalebar, 10 µm.
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Once the sample mounting and imaging conditions were optimized, we proceeded with
the objective of recording tumour organoid regression. Video stills in the Figure 3.19
show that imaging this process from the point of de-induction of oncogenes to almost 72
hours OFF DOX, is indeed possible. The inlay images in Figure 3.19 show the same single
cell marked with a blue dot in the entire time frame. The cell looks to have journeyed
from the center of the tumour organoid at 9 hours OFF DOX to integrating into the
regressed rim at 33 hours OFF DOX. Clearly these movies of tumour regression already
show some interesting phenomenon exhibited by cells during regression — cell movement
to the basement membrane and repolarization into the epithelial monolayer as a method
of survival.
But these anecdotal observations could not be reproduced simply because the datasets
are too convoluted for the current image analysis methods described in detail in the pre-
vious project of this thesis (Figure 2.10). Inability to segment these structures into single
cells in 3D impedes tracking their movement, divisions and apoptosis. Figure 3.20a shows
the raw images (left panels) and resultant pixel probability maps (right panels) for two
images of varying complexity. The lower panel images are from a tumour acinus and the
upper panel images are from a never induced acinus – both recorded at the InVi SPIM
during 96-hour image acquisitions. Clearly the algorithm cannot correctly classify pixels
in the chaotic tumour acinus 2D frame efficiently.
To circumvent this technological deficit, we propose a lentiviral delivery system to
stochastically mark single cells within an organoid before induction and de-induction
of oncogenes (Figure 3.20b). Introducing, via lentiviral delivery, a reporter fluorophore
(H2B-GFP) into some of the acinar cells before induction with doxycycline will allow us
to selectively image them in a separate channel without the chaotic microenvironment.
This imaging and image analysis modality are similar to the one successfully used for the
stochastic model mentioned in the previous project. Two channel imaging with randomly
marked tumour cells should therefore be able to simplify segmentation, allowing for track-
ing of some cells, if not all, during tumour regression. This imaging and data analysis are
planned for my bridging postdoctoral period after PhD defence.
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Figure 3.20: (a)Example segmentation using the CATS tool (Fiji) that uses a machine
learning algorithm to classify image pixels via feature identification. Left panels show
raw image planes(grey- H2B mCherry) and right panels show segmentation results (pink-
nucleus boundary pixel class; green- nucleus center pixel class). (b) Schematic showing
lentiviral marking strategy to reduce complexity of images recorded and simplify segmen-
tation.
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3.4 Discussion
The rationale for targeting breast cancer residual disease is clear from the clinical situ-
ation today. Upon treatment with targeted therapeutics, designed to specifically inhibit
oncogenes, 30-40% of patients who receive satisfactory remission with targeted therapy,
present with relapse tumors. This tumor recurrence is frequently attributed to residual
disease: a reservoir of tumour cells that evade primary therapy and persist in a dormant
state for long periods. This reservoir of cells represents a black box in terms of availability
of patient material. This has resulted in our limited understanding of the mechanisms of
residual disease survival and the molecular players that facilitate therapy evasion.
To address the need of molecular targets to combat this disease reservoir, we mod-
elled an in vitro substrate of this disease using cells from an inducible mouse model. As
described in the results section, this reconfirmed the observation [52] that the residual
population of cells resulting from ideal targeted therapy (oncogene de-induction) were
indeed not transcriptomically similar to their oncogene nascent (never induced) counter-
parts. RNA Seq analysis at the identified hallmark timepoints along the time course of
establishment of a residual disease substrate further informed us of the demarcation be-
tween oncogene regulated pathways (Expected Up and Expected down clusters in Figure
3.7) and novel pathways triggered by oncogenic shock (Table 3.2). These pathways could
be targeted to induce synthetic lethality in residual disease cells and represent a gene sig-
nature evolution that could be interfered with at multiple points during and after tumour
regression (Objective 1).
Further, we performed in-depth analysis of the immune proficient mouse model during
tumour regression, establishing time lines for tumor growth and regression in the animals
based on IHC staining. We used these time lines to select time points for microarray anal-
ysis. Analysis of the transcriptomic data during mouse tumor regression, corroborated
the finding that novel pathways are activated during tumour regression, independent of
the oncogene and distinct from normal cells(Objective 2).
The subset of signalling pathways that could be validated both in the mouse model
and its reductionist in vitro counterpart were evaluated for potentially synthetic lethal
targets. Careful analysis of the molecular players in the pathways identified warranted
the selection of Bcl6, c-Jun and the molecular players in the NF-κB cascade, as potential
synthetic lethal targets(Objective 3). Below is a bullet list of biological findings that
support the selection of each of these targets.
BCL6
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• BCL6 rests at the centre of the DNA Damage Response pathway shown to be dys-
regulated during residual disease establishment in our model system. BCL6 has
been shown to reduce the cells sensitivity to DNA damage [177] due to its direct
repression of the ATR gene, which prevents DNA-damage responding ATR targets
from being expressed. BCL6 also directly represses the CHEK1 gene, which is a crit-
ical mediator of the ATR-dependent DNA damage-signaling pathway[178]. BCL6
can also directly repress the TP53 and CDKN1A genes, thus severely impairing the
function of cellular DNA damage checkpoints at multiple levels [179][180]. All these
genes have also been downregulated significantly during tumour regression in the in
vitro 3D culture model.
• BCL6 is a transcriptional repressor protein that confers B-cells the ability to tol-
erate rapid proliferation and simultaneous genetic recombination[181]. This ability
conferred in residual cells could allow therapy evasion.
• In germinal centers (GC) (transient and dynamic cellular compartments that form
within secondary lymphoid organs), BCL6 plays a big role in B-cell maturation to
generate antibodies against specific antigens [182]. It does so by allowing rearrange-
ment and mutation of the immunoglobulin loci [183]. This points to a phenotype
of physiological genomic instability induced by BCL6 that could lead to cancer.
Naturally, genetic lesions that cause constitutive expression of BCL6 in GCs are
commonly associated with diffuse large B-cell lymphomas (DLBCL) [184] [185].
• BCL6 is expressed in most breast cancer cells lines and that its genetic locus is
amplified in approximately 50% of breast tumour samples. Studies targeting BCL6
have proven its importance for breast cancer [175].
• Higher BCl-6 expression reduces relapse free survival in HER2+ patients (OnlineKM
plotter [176]).
c-JUN
• c-Jun in combination with c-Fos, forms the AP-1 early response transcription factor.
It has been implicated in many cancers as a potent oncogene. Naturally, seeing this
gene upregulated in the residual cells (validated even on a protein level both in vitro
and in vivo) motivated us to test its synthetic lethality.
• c-Jun has been shown to mediate an anti-apoptotic function in response to TNFα.
TNFα is upregulated in our models during tumour regression and we hypothesized
that c-Jun overexpression in some cells was protecting them from apoptosis [186].
94
Quest for the Achilles’ heel in breast cancer residual disease
• In breast cancer modelling with HER2 over-expression (analogous to the mouse
model we employed with out rat Neu oncogene), the knocking out of of c-Jun, re-
duced cellular migration, invasion, and mammosphere formation of ErbB2-induced
mammary tumours[187]. In this study, researchers have shown that secreted inflam-
matory cytokines like CCL5 – induced by ErbB2 expression — were dependent upon
endogenous c-JUN expression and that CCL5 rescued the c-Jun-deficient breast tu-
mour cellular invasion phenotype. Since CCL5 was also upregulated in our model of
tumour regression, both in vitro and in vivo, we postulated an intertwined signalling
between these two targets.
• A study analyzing gene expression data derived from serial tumour samples of pa-
tients with breast cancer who received Neo-Adjuvant Chemotherapy (NAC) in the
I-SPY 1 TRIAL showed that the key transcriptional regulator AP-1, JUN and FOSB
were among the 32 upregulated genes in residual tumours after chemotherapy. This
points to a human relevance of c-JUN in residual disease [188].
Molecular players in the Nf-κB cascade
As mentioned above, the TNFα upregulation during the process of tumour regression
observed in our model, propelled interest in the cascades activated by this cytokine. TNFα
induced NF-κB activity seemed like a viable downstream progression – especially since
all the NF-κB subunits were also upregulated in our transcriptomic data. We proposed
that this TNFα induced NF-κB activity was causing the upregulation of anti-apoptotic
mediators like Bir2, Birc3 and BCl2l2 (all of which are enriched in the residual cell tran-
scriptome). These observations warranted targeting of the NF-κB activation cascade. We
tried to do this using IKK2 inhibitors (Table 3.3). IKK2 is a multiprotein kinase complex
that is responsible for the TNFα induced phosphorylation of IκB(Inhibitor of κB) which
then dislocates and allows the NF-κB transcription factor to translocate to the nucleus
and induce expression of certain genes. Another interesting target in this cascade was the
inflammatory cytokine CCL5.
CCL5
• CCL5 has been shown to play an important role in many facets of tumour pro-
gression, such as invasion, metastasis, neoangiogenesis, and immune cell infiltration
[189].
• In TNBC (triple negative breast cancer) patients , CCL5 expression has been shown
to be enriched in larger tumours remaining after neoadjuvant chemotherapy indicat-
ing it’s role in residual disease survival [190].
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• In prostate cancer, the role of CCL5 in proliferation and metastasis was shown to be
mediated through F-actin polymerization and Maraviroc, a CCR5 antagonist was
successfully used to block it’s effects [191] [192]
• In gene expression data-sets from breast cancer patients treated with neoadjuvant
targeted or chemotherapy [193] [194]), CCL5 expression is elevated in residual tu-
mour cells that survive therapy [195].
• Another group at Duke University recently published data with the same inducible
mouse model used in this project. They also observe that oncogene withdrawal led
to hyperactivation of the NF-κB pathway and downstream upregulation of CCL5.
Confirming our hypothesis, they prove that this program was mediated by autocrine
TNFα and dependent upon IKK/NF-κB signaling [195](also shown recently in lung
cancer [196]). They implicated CCL5 in macrophage recruitment, collagen deposi-
tion and tumour recurrence.
The targets detailed above were tested using the screening pipeline (see Figure 3.13,
Table 3.3) and residual disease cells that were treated with target inhibitors were as-
sayed for viability and cell death. The experimental readouts for all inhibitors indicate
that although the inhibitor severely reduces residual disease viability at higher doses, this
correlate is far more refractory than normal never induced mammary organoids. These
results indicate that the in vitro testing assay might not be the optimal readout for assess-
ing synthetic lethality. 90% of the tumour mass apoptoses upon removal of doxycycline
from induced organoids and the cell viability/death assay read outs might not be sensitive
enough to record the additional 1% death caused by synthetic lethality of the proposed
targets. Therefore, alternate validation methods will be required to validate the “synthetic
lethality” of these targets. An in vivo validation in mice with a “Relapse free survival”
read out might be an ideal method of target validation, given that prevention of relapse
in inhibitor treated mice might be considered cure because of the eradication of residual
cells with repopulating potential.
In an effort to identify targets in a more biased approach – observing regressing cells
and identifying their vulnerabilities in a spatio-termporal dimension – we set up live cell
imaging using light sheet microscopy for regressing tumour organoids (Objective 4).
As described earlier, the inner core of a tumour organoid in vitro undergoes rapid
apoptosis upon removal of doxycycline from the media and we see repolarized epithelial
rims within 72 hours of oncogene inactivation. So far, we do not know, how cells rearrange
during this process to form a repolarized, surviving rim after 72 hours. Is there any traf-
ficking of survivor cells from the core to the edge to form part of the re-polarized rim? Or
do the inner cells apoptose simply because they do not have connection to the basement
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membrane to latch onto, activate signaling pathways and survive? Clarification of these
spatio-temporal dynamic mechanisms is hypothesized to point to possible interference ap-
proaches. For example, blocking of integrin signaling could be synthetic lethal in case we
observe a major involvement of basement membrane signaling for survival in the residual
cells.
Big-data analysis work-flows allow for visualization of tumour regression in 3D but
current machine learning algorithms cannot segment these regressing tumour data-sets
to allow for single cell tracking. To circumvent this hurdle, lentiviral reporter delivery is
currently being adopted to allow for simplified segmentation and tracking (Figure 3.20).
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3.5 Conclusions
Tumor recurrence is a major cause of death in women with breast cancer. Tumor re-
currence or relapse is attributed to a subset of cells that somehow circumvent targeted
therapeutics and lay dormant before resulting in refractory relapse tumours. These resid-
ual cells are a black box of patient material and consequently their molecular mechanisms
are yet to be fully understood.
Using an inducible mouse model of breast cancer, we modelled residual disease us-
ing organoid cultures and characterized them during tumor regression using IF staining.
We further explored this dynamic process of tumor regression and residual disease es-
tablishment on a transcriptomic level, using RNA sequencing at hallmark time points.
Identification of hallmark time points during tumor regression coupled with kinetic tran-
scriptome data further expanded our understanding of the pathways activated when a
tumor organoid is no longer expressing oncogenes and is undergoing massive apoptosis. In
addition to oncogene dependant signalling pathways, our sequencing data revealed a tran-
scriptomic signature unique to residual tumor cells and provided the possibility to explore
associated molecular pathways that could be responsible for their survival. Once equipped
with this information that we derived from clean, reductionist 3D culture organoids, we
aimed to validate them in the immune proficient conditions of the mouse model.
We performed an in depth characterization of the regressing mammary glands of mice
using IHC staining and the transcriptomic analysis performed along the course of in vivo
mouse tumor regression was overlaid onto the in vitro regression transcriptome. Molecular
targets identified in the organoid cultures and validated in the mouse mammary glands,
such as c-Jun, BCL6 and players of the Nf-κB cascade, were then evaluated for their syn-
thetic lethality in vitro, although more robust, sensitive and relevant methods of assessing
synthetic lethality need to be established.
In a more biased approach, to unravel the mechanisms of residual disease establishment
in our in vitro tumour organoids, we set up long-term live cell imaging of regressing
organoids using light sheet microscopy. Imaging movies that we recorded show some
interesting anecdotal characteristics exhibited by cells during regression — cell movement
to the basement membrane and repolarization into the epithelial monolayer as a method
of survival. Athough our efforts in unravelling the spatio-temporal dynamics of tumor
regression are currently impeded by image analysis limitations, we intend to circumvent
them as detailed in the project above.
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Contributions:
This thesis contains experiments performed by me in conjunction with members of the
Jechlinger Group and analyzed with the help of various collaborators at EMBL, Heidel-
berg.
I cultured mammary organoids for all experiments, genotyped mice, performed regular
checks of the mouse colony, harvested in vivo samples and performed the various analy-
ses using bright-field, confocal and light-sheet microscopy. I also performed all the im-
munohistochemistry stains, immunofluorescence stains, Real-Time qPCR analysis, RNA
extractions and image analysis workflow implementations described in this thesis.
Ksenija Radic (Jechlinger Group, Cell Biology and Biophysics Unit, EMBL Heidel-
berg) contributed significantly to the in vitro culture experiments including doxycycline
titration, IF staining and collection and extraction of RNA.
Lucas Chaible (Jechlinger Group, Cell Biology and Biophysics Unit, EMBL Heidelberg)
set up the stochastic tumorigenesis system including cloning, organoid transduction and
lentivirus production experiments and contributed to imaging experiments.
Sabine Reither (Advanced Light Microscopy Facility, EMBL, Heidelberg) was con-
sulted during imaging experiments and helped set up light sheet imaging.
Christian Tischer (Center for Bioimage Analysis, EMBL, Heidelberg) created the tools
for SPIM data processing and segmentation. He also consulted on Imaris software usage
and contributed to figure design and manuscript writing.
Jean-Karim Heriche performed computational feature analysis for single cells of the
stochastic tumor organoids.
Katharina Zirngibl (Patil group, Structural and Computational Biology Unit, EMBL
Heidelberg) performed RNA-sequencing data analysis (differential expression analysis,
clustering analysis, correlation analysis for gene expression profiles and manual curation
of clusters and gene targets).
Matt Rogon (Centre for Biomolecular Network Analysis, EMBL Heidelberg) performed
the Gene Enrichment analysis and Network analysis for identification of synthetic lethal
targets.
Ksenija Radic, Savannah Jackson and Marta Garcia Montero ( all from the Jechlinger
Group, Cell Biology and Biophysics Unit, EMBL Heidelberg) helped maintaining the
mouse colony and harvesting samples. Marta Garcia Montero also provided technical
assistance with histology.
Sylwia Gawrzak (Jechlinger Group, Cell Biology and Biophysics Unit, EMBL Heidel-
berg) helped design and perform experiments for synthetic lethal inhibitor testing using
in 3D vitro cultures
Yuanyuan Chen (Sotillo Group, DKFZ, Heidelberg) helped perform IHC experiments
and subsequent imaging.
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RNA sequencing and RNA microarray-chip runs were performed at the Genomic Core
Facility at EMBL.
Dr. Martin Jechlinger supervised the project, designed experiments and contributed
to manuscript writing.
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1. Tracking the cells of tumor origin in breast organoids by light sheet
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Hériché, JK and Tischer, C and Jechlinger, M
bioRxiv, 2019, 617837; DOI: https://doi.org/10.1101/617837.
2. Towards a holistic and mechanistic understanding of tumourigenesis via
genetically engineered mouse models
Ashna Alladin and Martin Jechlinger
Current Opinion in Systems Biology, 2017; Volume 6, Pages 74-79, 2452-3100. DOI:
10.1016/j.coisb.2017.10.004
3. Metabolic shifts in residual breast cancer drive tumor recurrence
Kristina M. Havas, Vladislava Milchevskaya, Ksenija Radic, Ashna Alladin, Eleni
Kafkia, Marta Garcia, Jens Stolte, Bernd Klaus, Nicole Rotmensz, Toby J. Gibson, Bar-
bara Burwinkel, Andreas Schneeweiss, Giancarlo Pruneri, Kiran R. Patil, Rocio Sotillo,
Martin Jechlinger
J Clin Invest. 2017; 127(6):2091-2105. DOI:10.1172/JCI89914.
101
Materials and Methods
4.1 Animal models
The mouse strains TetO-MYC/ MMTV-rtTA [87] and TetO-Neu/ MMTV-rtTA [48], that
have been described previously, were bred in order to establish the tri-transgenic strain
TetO-MYC/TetO-Neu/ MMTV-rtTA or bi-transgenic strain TetO-MYC/TetO-Neu. Re-
porter H2B-mCherry was crossed into the B and T lines using a R26-H2B-mCherry line
[197] (RIKEN, CDB0239K). The mice were all bred in FVB background. Animals were
kept on a 12-hour light/12-hour dark cycle, with constant ambient temperature (23±1◦C)
and humidity (60±8%), with pellet food and water ad libitum. Food pellets containing
doxycycline (doxycycline hyclate 625 mg/kg) were obtained from Envigo Teklad. Breeding
and maintenance of mouse colony was done in LAR (Laboratory Animal Resources) facility
of EMBL Heidelberg, under veterinarian supervision and in accordance to the guidelines
of the European Commission, revised Directive 2010/63/EU and AVMA Guidelines 2007.
4.1.1 Genotyping
After weaning, the LAR facility at EMBL, Heidelberg provided tail/ear cuts from all
the mice and their genotypes were then determined by PCR on genomic DNA. Genomic
DNA was extracted by digesting the tail/ear piece in 75 µl of digestion buffer (NaOH
25 mM, EDTA 0.2 mM) in an Eppendorf tube at 98◦C for 1 hour at 1000 rpm shak-
ing. Then, the solution was neutralized by addition of 75 µl Tris-HCl (40 mM, pH
5.5). The tube was then centrifuged at 4000 rpm for 3 min. 2 µl of the supernatant
was used in the PCR reactions. Primer sequences for the transgenes used are as fol-
lows: Tet-O Neu (Forward: GACTCTCTCTCCTGCGAAGAATGG and Reverse: CCT-
CACATTGCCAAAAGACGG); Tet-O MYC (Forward: TAGTGAACCGTCAGATCGC-
CTG and Reverse: TTTGATGAAGGTCTCGTCGTCC); MMTV-rtTA (Forward: GT-
GAAGTGGGTCCGCGTACAG and Reverse: GTACTCGTCAATTCCAAGGGCATCG).
Agarose gel-electrophoresis was used for the detection of PCR products (MYC 630 bp, Neu
386 bp, rtTA 380 bp), which was done on the 1.5 % agarose (Sigma, Cat. #A9539-500G)
gel with Ethidium bromide solution in a final concentration of 0.5 µg/ml (Sigma, Cat. #
E1510-10ML). The products were visualized using Quantum-Capt1 documentation system
and instrument (Peqlab).
4.1.2 In vitro experimental design
Female virgin mice of the desired genotype and between 8-10 weeks old were sacrificed by
asphyxiation and dissected with a small cut at the level of the pubis, followed by a median
longitudinal cut superior to the chin. The skin was then dissected and turned on one
side exposing the the subcutaneous, superficial lymph nodes and mammary glands. All
ten mammary glands were harvested, digested and singularized for establishing organoid
cultures
102
Materials and Methods
4.1.3 In vivo experimental design and harvest
In vivo tumour formation and regression was achieved by regulating doxycycline in the
animal diet for TetO-MYC/TetO-Neu/ MMTV-rtTA animals. For induction of tumours,
food pellets supplemented with doxycycline (625 mg/kg) was given to the mice once they
reached 8 weeks of age. Animals were monitored weekly for tumor development and overall
health. Full blown tumors developed in the period of 4-8 weeks in triple transgenic mice.
When the tumour burden was too large (diameter of the largest nodule was more than 2
cm), animals were given food without doxycycline which resulted in the fast tumour re-
gression to a non-palpable state. After 9 weeks of doxycycline withdrawal from the animal
diet the tumours were considered fully regressed. Wild-type (or non-inducible) siblings
were treated in the same way alternating food containing doxycycline. They represented
age-matched controls and were harvested at the same time and in the same manner. Har-
vesting triple transgenic animals at the point of high tumor burden or along the regression
phase (after doxycycline withdrawl) was done in an organized fashion. Before harvesting,
the mice were evaluated for the phase of estrous cycle they were in, by taking vaginal
smears according to the modified protocol in [198]: 20-40 µl of 1x Phosphate Buffered
Saline (PBS) was used to obtain vaginal lavage. The smears were dried on the slide at
room temperature and further fixed in 10 % formalin, washed in 1x PBS, stained with
Crystal Violet solution (Sigma, Cat. # V5265) washed in tap water and visualized using
Leica Application Suite X and Leica DFC7000 T microscope (Leica Microsystems). If
the mice were found to be in Diesterous phase of the esterous cycle, harvest was post-
poned by 1-3 days. If the esterous cycle phase was evaluated to be ideal for harvest, the
mouse was first sacrificed by asphyxiation. Then the external appearance was recorded
by photographing. The mouse was dissected open and all affected mammary glands were
removed and the tumour material was partitioned for paraffin embedding (for histology
staining), OCT embedding (for cryo-histology) and tissue freezing (in liquid nitrogen to
preserve DNA, RNA and protein).
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4.2 3D Cell culture
4.2.1 Matrigel culture
Mammary glands harvested from mice (see above), were digested in order to prepare a
single cell solution. For this, the tissue was divided in four loosely capped 50 ml falcons,
each supplemented with 5 ml serum-free media (DMEM/F12 supplemented with 25mM
HEPES and 1% Pen Strep (100 U/ml Penicillin; 100 µg/ml Streptomycin; ThermoFisher
Cat. # 15140122)), 750 U of Collagenase Type 3 (Worthington Biochemical Corp, Cat.
# LS004183), 20 µg of Liberase (Roche Cat. # 5401020001) and incubated overnight
(not more than 16 hours) at 37◦C and 5%CO2. The glands were then mechanically
disrupted using a 5 ml pipette, and washed in PBS before being pelleted at 1000 rpm
for 5 minutes. The interphase between upper fat layer and cell pellet was removed and 5
ml of 0.25% Trypsin-EDTA (Invitrogen, Cat.# 25200-056 ) was added and incubated for
45 minutes at 37◦C and 5%CO2. The enzymatic reaction was then neutralized using 40 ml
of serum supplemented media (DMEM/F12 with 25mM HEPES, 1% Pen Strep and 10%
FBS Tetracycline Free certified (Biowest Cat. # S181T)). The cells were pelleted again,
resuspended in Mammary Epithelial Cell Basal Medium (PromoCell Cat. # C-21210)
and seeded in collagen coated plates (Corning Cat. # 354400) overnight at 37◦C and 5%
CO2. This allows for epithelial cells to adhere to the surface of the plates while the other
cell types float on top in the media and can be easily removed by vacuum suction. The
epithelial cells were detached from the collagen coated plates by incubating them with
0.25% Trypsin-EDTA for 5-7 minutes at 37◦C and 5%CO2, following inactivation with
serum supplemented media. The single cell solution was pelleted, resuspended in MEBM
and counted. For seeding 3D culture gels, typically 10,000-12,000 cells we mixed rapidly
on ice with the prepared Matrigel-collagen mixture – 4:2:1 proportions of Matrigel Matrix
basement Membrane growth factor reduced phenol red free (Corning Cat. # 356231),
Cultrex 3D Collagen I rat tail (TEMA Ricerca, Cat. # 3447-020-01) and cell suspension
diluted in PBS(1x) respectively. Matrigel-collagen-cell mixture droplets 100 µl in volume
, were then dispensed into flat bottom wells (Corning CellBIND 12 Well Clear Multiple
Well Plates, Cat. # 3336) and incubated for 30-40 minutes at 37◦C and 5%CO2, until the
matrigel solidified. The gels were supplemented with 1.5 ml MEBM and allowed to grow
at 37◦C and 5%CO2.
For induction of oncogenes in the cells of the organoids, doxycycline (Sigma Cat. #
D9891) was supplemented in the media. During oncogene de-induction of the organoids
the media supplemented with doxycycline was removed from the plate wells and the gels
were washed thrice for 10 mins, using serum supplemented media, PBS(1x) and serum
free media, in that order.
For RNA seq sample collection experiments, from the start of experiment until collec-
tion, media was changed every alternate day at precisely the same time. An extra media
change was performed after 24 hours following the de-induction of oncogenes by removing
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doxycycline.
4.2.2 Organoid transduction
For transduction of organoids either with Inducer-reporter (pLenti-rtTA-GFP) lentiviral
particles or Reporter (pLenti-GFP) lentiviral particles transduction, Matrigel cultures
were established as mentioned above. After 3 days of growth, the gels were mechanically
disrupted and placed in a 15 ml falcon. Two disrupted gels were placed in one 15 ml falcon
with 2ml of MEBM supplemented with 25U of Collagenase type I and 5 µg of Liberase.
Following incubation in this solution for 2 hours at 37◦C and 5%CO2, when the matrigel
was totally digested, the organoids were washed 3 times with 15 ml of serum supplemented
media and once with 15 ml of serum free media, and pelleted at 1000 rpm for 5 minutes.
We then supplemented the organoid pellet (from two original gels) in 10 µl of MEBM and
added 6 x 105 lentivirus particles to the solution. We then mixed this solution with 90 µl
matrigel and plated it in 35 mm dishes (Greiner Bio-One Cat. # 627160) and placed in
incubator for 30-40 minutes until the matrigel solidified. The gels were supplemented with
3 ml MEBM and incubated for 2 days at 37◦C and 5%CO2 in order to allow for organoid
recovery and lentiviral gene expression.
For induction of oncogenes in the cells of the organoids, doxycycline (Sigma Cat. #
D9891) was supplemented in the media. 800 ng/ml of doxycycline was used to induce
tri-transgenic organoids and 600 ng/ml was used for the bi-transgenic organoids. qPCR
analysis was used to standardize the doxycycline dosage for bi-transgenic organoids.
4.2.3 Target validation pipeline
For testing synthetic lethality of identified targets, target inhibitors were supplemented
in the media during tumour regression of organoids grown in 96 well plates (Falcon R©
96-well Black/Clear Flat Bottom TC-treated Imaging Microplate with Lid, Corning, Cat.
# 353219). Brightfield imaging was performed to follow the organoid regression visually
and cell assays were implemented at end points to ascertain cell viability and cell death.
Mouse mammary glands were harvested and processed into single cell suspension as
detailed above. Matrigel-cell suspension mixture was prepared on ice as usual, consisting
of Matrigel:CellSuspension ratio in 2:1 part. The mixture contained 10,000 cells per 100
µl. Small 5 µl gels were seeded into the wells of a 96 well plate from this mixture, resulting
in 500 cells dispensed into each well. The gels were incubated for 30-40 minutes at 37◦C
and 5%CO2, until the matrigel solidified. Using a multi-channel pipette, 200 µl of MEBM
was supplemented into each well of the 96 well plate and the gels were allowed to grow
at 37◦C and 5%CO2. Wells on the corners were not used to prevent edge-effect of assay
readouts and other anomalies in culture systems frequently experienced.
Media was replenished every alternate day to support growth of single cells into
organoids. After 4-5 days of normal growth, the media was supplemented with 200 ng/ml
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of doxycycline. Induction of oncogenes with doxycycline was carried out for 5 days via
usual media replenishment. After 5 days of maintaining the 3D cultures on doxycycline,
the gels were washed thrice for 10 mins, using serum supplemented media, PBS(1x) and
serum free media, in that order. MEBM with increasing concentrations of the inhibitor of
choice was added along with the necessary controls. Five technical replicates were analysed
per condition. Normal uninduced cells, grown alongside induced tumours, were used as
internal controls to test for the toxicity of the inhibitor being tested at all concentrations.
Gels were supplemented with media and supplements every alternate day as usual. Seven
days after de-induction and addition of inhibitors, the experiment had reached it endpoint
and was processed for cell viability and cell death assays.
Inhibitors tested via this assay included: BCL6 Inhibitors: 79-6 (Calbiochem, Cat.
# 197345), FX-1 (MedKoo, Cat. # 407501) c-Jun Inhibitors: Tanshinone IIA -AP-1
inhibitor (Enzo, Cat. # BML-GR336-0005), SP 600125 (Tocris, Cat. # 1496/10). Nf-kB
Pathway Inhibitors: CCL5 Inhibitor- Maraviroc (Sigma, Cat. # PZ0002), IKK-2 Inhibitor
IV - CAS 507475-17-4(Merck, Cat. # 401481), IKK-2 Inhibitor VIII - CAS 406208-42-2
(Merck, Cat. # 401487)
ScanR imaging and data representation
Inhibitor testing experiments performed in all 96-well plates were imaged on the ScanR
(High Content Screening Station, Olympus) immediately after de-induction and at “Day0”
of inhibitor treatment and then again after seven days at “Day 7” of inhibitor treatment.
4x objective was used to image the 3D cultures in 4 quadrant fields of view per well. 21
images were recorded at z-step intervals of 100 µm in each of the four fields of view to
cover the entire three-dimensional range of organoids occurring in the gel. The z stacks
in each field of view were processed to show a “maximum projection” image and all 4
maximum projections per well were “stitched” together to get an overview of the whole
gel drop in each well. Custom-made codes, including the macros created by the Advance
Digital Microscopy Core Facility at IRB Barcelona used for image analysis, are available
upon request from the authors of Gawrzak, et al., 2018 [199].
Cell Titre Glow and CellTox assay multiplexing
At the end point of each inhibitor validation experiment, i.e., after seven days of oncogene
de-induction and Day 7 of inhibitor treatment, the cultures were assayed for cell viability
and cell death. After removal of 100 µl of media from each well, 20 µl of the working solu-
tion of CellToxTM Green Cytotoxicity Assay (Promega, Cat. # G8741) was added to the
media in each well and the whole plate was gently shaken at room temperature for 1 hour.
The CellToxTM Green Cytotoxicity Assay is based on detection of biomarkers released
into the medium upon cell death and membrane perforation. The substrate in the assay
binds to the cytotoxic indicator markers and produces a green fluorescence signal that is
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proportional to overall cell death in each matrigel culture drop. The fluorescence from
the whole 96-well plate was recoded at the Chemical Core Facility at EMBL Heidelberg,
using a EnVisionTM Multilabel Plate Reader (PerkinElmer).
After recording the cell death, 50 µl of CellTiter-Glo R© Luminescent Cell Viability
Assay (Promega, Cat. # G7570) was added to the media in each well and the whole plate
was gently shaken at room temperature for 1 hour. CellTiter-Glo R© Luminescent Cell
Viability Assay is a method of determining the number of viable cells in culture based
on quantitation of the ATP present, an indicator of metabolically active cells. The assay
results in cell lysis and generation of a luminescent signal proportional to the amount of
ATP present. The amount of ATP is directly proportional to the number of cells present in
culture. It generates a ”glow-type” luminescent signal that was measured similarly, using
a EnVisionTM Multilabel Plate Reader (PerkinElmer), at the Chemical Core Facility at
EMBL Heidelberg, in RLU (relative luminescence units).
Raw data from the plate reader was analysed to ascertain the inhibitor’s effect on the
never induced and regressed organoids. This was done by constructing a dose-response
curve. A dose-response curve describes the relationship between increasing the dose (or
concentration) of the drug (inhibitor) and the change in response that results from this in-
crease in concentration. The concentration ranges spanned by the inhibitors are indicated
in Table 3.3. The dose in these curves is usually represented using a semi-logarithmic plot.
On a semi-logarithmic plot, the amount of drug(inhibitor) is plotted (on the X axis) as
the log of drug concentration and response is plotted (on the Y axis)using a linear scale.
Dose response curve analysis and calculation of IC50 values for each drug and assay was
performed using the GraphPad 6 (Prism) statistical analysis software.
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4.3 Immunofluorescence staining
Matrigel cultures required for immunofluorescence analysis were grown as described in
Section 4.2 on either NuncTM Lab-TekTM II chambers (Thermo Cat. # 155382) or on
glass slides placed in 12-well tissue culture plates (Corning CellBIND 12 Well Clear Mul-
tiple Well Plates, Cat. # 3336). At pre-defined timepoints, the gels were transferred to
deactivated clear glass screw neck vials (Waters Cat.# 186000989DV) and fixed using 4%
PFA for 2-3 mins, following three 10 min washes with PBS (1x) and one 20 min wash
with IF buffer (containing NaCl, Na2HPO4, NaN3, BSA, TritonX-100, Tween-20; pH
7.4). The gels were blocked with Blocking Buffer (1x IF buffer with 10 % goat serum
(Jackson Immuno Research Cat.# 005-000-121)) for 2 hours at room temperature. The
gels were incubated with primary antibodies (diluted in Blocking Buffer) overnight at 4◦C
and washed 3 times the next day in 1x IF buffer for 20 mins per wash. Glass vials were
then covered in aluminum foil and the gels were incubated in blocking buffer with sec-
ondary Alexa antibodies and DAPI (4’, 6’-diamino-2-phenylindole) (ThermoFisher Cat.
# 62248, ddilution 1:1000) for 1 hour. Following incubation with secondary Alexas and
DAPI, the gels were washed briefly in PBS(1x) for 5 mins. The gels were then trans-
ferred to a NuncTM Lab-TekTM II chamber and mounted in anti-fading mounting medium
VECTASHIELD R© Mounting Medium with DAPI (Vecto Cat. # H1500-10). Stained gels
were imaged on Leica SP5 confocal microscope using 63x water lens and the LAS AF
imaging software.
The following primary antibodies and dilutions were used for Matrigel cultures: c-MYC
(Cell Signaling Technologies, Cat. # D84C12, dilution 1:900), alpha6-integrin (Millipore
Cat. # MAB1378, dilution 1:80), ZO1 (Life Technologies Cat. # 61-7300, dilution 1:500),
GM-130 (BD Biosciences Cat. # 610823, diluted 1:100), E-cadherin (Invitrogen Cat. #
3-1900, diluted 1:200) , Cleaved Caspase3 (Cell Signalling, Cat. # 9661S, diluted 1:100),
c-Jun (Cell Signalling (60A8), Cat. # 9165, diluted 1:100 ) and BCL6 (Atlas antibodies,
Cat. # HPA004899, diluted 1:50). Anti-rabbit, anti-mouse, and anti-rat antibodies were
purchased coupled with Alexa Fluor dyes (Invitrogen, Cat.# A21247, A11034, A11036)
for secondary staining.
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4.4 Immunohistochemistry staining
Harvested mammary gland tissue and tumor tissue during progression and regression was
fixed in 10 % formalin solution (neutral buffered; Sigma, Cat.# HT501128-4L) overnight
on a shaker to allow optimal penetration of fixing agent. Subsequent to embedding in
paraffin via standardized procedures, the embedded tissue was sectioned at 5 µm thickness
with a microtome (Leica, Cat.# RM 2135) and placed on slides (Superfrost , Cat.#
VWR630-0954). Tissue sections were incubated at 37◦CC for 16 hours before storage
and further staining. Staining by Hematoxylin QS (Vector, Cat.#H-3404) and Eosin 1 %
Aqueous (RA Lamb, Cat.# LAMB/100-D) was done following the standard protocol and
samples were analyzed at microscope (Leica, Cat.# LMD 7000).
Cleaved Caspase3 (Cell Signalling, Cat. # 9661S, diluted 1:100), c-Jun (Cell Signalling
(60A8), Cat. # 9165, diluted 1:350 ), BCL6 (Atlas antibodies, Cat. # HPA004899, di-
luted 1:750) and Ki67 (Vector, Cat.# VP-K451, diluted 1:100) antibody staining was done
on FFPE tissue following the standard IHC protocol: deparaffinization and rehydration
of the samples, followed by antigen retrieval using citric acid-based Antigen unmasking
solution (Vector, Cat.# H-3300) for 30 min in a steamer and inactivation of endogenous
hydrogen peroxidase activity with 10 % H2O2 solution (Sigma, Cat.# H1009) for 10-15
mins. Blocking was done using 10 % Normal goat serum (Jackson Immuno Research,
Cat.# 00500121) in 1x Phosphate Saline Buffer (PBS) for 2 hours, following incubation
with primary antibody (diluted in blocking buffer) at 4◦CC overnight. Next day, the slides
were washed 3 times for 5 mins each using PBS(1x). Incubation with biotinylated anti-
body from Vectastain Elite ABC HRP Kit (Peroxidase, Rabbit IgG; Vector Laboratories,
Cat.# PK-6101) was done for 30 min, followed by washing and incubation with Horse
Radish Peroxidase (HRP) conjugated antibody. Detection of antibody localization was
done using DAB Peroxidase (HRP) Substrate Kit (Vector, Cat.# SK-4100). Counter-
staining was done using Hematoxylin QS (Vector, Cat.#H-3404), after which the sections
were dehydrated, mounted with DPX Mountant for histology (Sigma, Cat.# 06522) and
analyzed using a wide-field microscope (Leica, Cat.# LMD 7000) equipped with Leica
CD310 digital camera and LASV3.7 (Leica) software.
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4.5 qPCR analysis
The qPCR technique was performed following the MIQE guidelines, where the total
RNA was isolated from the mammary gland organoids using RNA PureLink Mini Kit
(ThermoFisher Cat. # 12183018A) and 2.5ug was reverse transcribed to cDNA us-
ing SuperScript VILO cDNA Synthesis Kit (ThermoFisher Cat. # 11754050). Using
Primer3 software we designed specific primers for DNA intercalating fluorescent dye ap-
proach for the transgenes Neu (Forward: CGTTTTGTGGTCATCCAGAACG and Re-
verse: CTTCAGCGTCTACCAGGTCACC) and c-MYC (Forward: GCGACTCTGAG-
GAGGAACAAGA and Reverse: CCAGCAGAAGGTGATCCAGACT). As endogenous
controls, mCherry (Forward: GAGGCTGAAGCTGAAGGAC and Reverse: GATGGT-
GTAGTCCTCGTTGTG) and Pum1 (Forward: AATGTGTGGCCGGATCTTGT and
Reverse: CCCACAGTGCCTTATACACCA) were used. Primer efficiency was verified
and established between 95% and 105% Each sample was analyzed in duplicate and non-
template controls were used in each qPCR run. Analyses were carried out using a StepOne
device (Applied Biosystems, USA). Analysis of relative gene expression data was performed
according to the 2∆∆Cq method and the results were expressed as fold change of ∆∆Cq
values obtained from the reference T800 organoids.
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4.6 Lentivirus cloning and production
The lentivirus design is based on pWPXL backbone, which was a gift from Didier Trono
(Addgene Cat. #12257). The coding region from the original plasmid was excised using
ClaI and NdeI in order to insert a new multiple cloning site (MCS). The pGK promoter
was PCR amplified from pLVPT-GDNF-rtTR-KRAB-2SM2, which was a gift from Patrick
Aebischer Didier Trono (Addgene Cat.#11647) and cloned using XhoI and EcoRI restric-
tion sites. For the plasmid pLenti-rtTA-GFP the synthetic region rtTA-p2A-H2B-GFP
was cloned downstream of the pGK promoter using EcoRI and NheI sites. The plasmid
pLenti-Null-GFP is derived from the pLenti-rtTA-GFP by removing the rtTA sequence,
using the restriction sites EcoRI and BamHI, and retaining H2B-GFP in the coding re-
gion. For production of lentivirus particles, we seeded 1.6 x 107 HEK-293T cells (Lenti-X
- Clontech Cat. # 632180) in 500cm2 square dishes (Corning Cat. # 431110). Af-
ter 24 hours, the cells were supplemented with media containing 25uM of chloroquine
diphosphate (Sigma-Aldrich Cat. # C6628). After a 5-hour incubation, using 360 µg of
polyethyleneimine (4 µg for each µg of plasmid), we transfect the cells with a mixture
of endotoxin free plasmids: 20 µg pCMV-VSV-G (Addgene Cat. #8454); 30 µg psPAX2
(Addgene Cat.#12260); 40 µg transfer plasmids pLenti-rtTA-GFP or pLenti-Null-GFP.
We harvested the media 48 hours, 72 hours and 96 hours post transfection. Concentration
of the lentivirus from the collected media was performed using an ultracentrifuge (Beck-
man Sw32 rotor) at 25,000 rpm for 2 hours at 4◦C. The lentivirus pellet was resuspended in
1000 µl of HBBS buffer, aliquoted and stored at -80◦C. The lentivirus titer was measured
using FACS analyses as described by Kutner and colleagues [200].
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4.7 Selective Plane Illumination Microscopy
4.7.1 Sample holder preparation and mounting
Imaging was performed on the InVi SPIM (Inverted light-sheet microscope from Luxendo
Light-Sheet, Bruker Corporation). Sample mounting for the InVi SPIM is suitable for 3D
matrigel cultures that are used to grow and transduce mammary organoids (see above).
The sample holder is made of medical grade plastic (PEEK). A 25 µm thin membrane
(FEP; Luxendo) with a refractive index matching that of water is glued to the upper
surface of a groove in the sample holder with a biocompatible silicone glue (Silpuran 4200;
Wacker), forming a trough with transparent bottom. Matrigel cultures were carefully cut
with a scalpel into rectangular slivers and transferred onto the FEP membrane’s trough.
Once the gel sliver was aligned in place, 20-30 µl of fresh matrigel drops were poured onto
the gel sliver in the sample holder until there was a thin layer of liquid matrigel on top
of the gel sliver. The setup was incubated for 20 minutes at 37◦C in a 5% CO2 incubator
to allow the matrigel layer on top to solidify. Once the gel was solidified, 600-800 µl of
MEBM supplemented with/without doxycycline was added to the sample holder’s FEP
sheet trough. Preferably, freshly mounted sample gels were allowed to settle overnight
in the incubator to prevent any gel drift during imaging, when the holder is placed into
the imaging chamber of the microscope. The imaging chamber acts as an incubator with
environmental control and it has a reservoir for immersion medium, which is filled with
water so that both objective lenses and the bottom of the sample holder are below the
water surface.
4.7.2 Imaging configurations and conditions
The InVi SPIM is equipped with a Nikon CFI 10x/0.3NA water immersion lens for illumi-
nation and a Nikon CFI-75 25x/1.1NA water immersion lens for detection. For excitation
of GFP and mCherry, 488 nm and 594 nm laser lines were used, respectively, while emission
was selected using a 497-554 nm band pass filter and a 610 nm long pass filter, respectively.
3D image stacks were acquired with a light-sheet thickness of 4 µm, a final magnification
of 62.5x, resulting in 104 nm pixel size. The In-Vi SPIM environmental control was set to
37◦C, 5% CO2 and 95% humidity. A series of optimization experiments, involving different
laser powers, exposure times and z-step sizes yielded laser powers of 13 µW for 488 nm and
36 µW for 594 nm, 100 millisecond exposure time per frame and 1µm z-spacing between
frames to be optimal for long term imaging (96-120 hours) without photo-bleaching or
photo-toxic effects on growth. Images were recorded as 2D planes ranging from 100-500
in number, depending on the organoid size. Each 3D stack of planes was recorded in 2
channels - mCherry (all cells) and GFP (transduced cells). Depending on the duration of
the time lapse imaging, 450-600 image stacks (equivalent to 72-96 hours) were recorded
per organoid at 10-minute intervals.
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4.7.3 Big-image data analsysis workflow
Big Data Processor, a Fiji plugin for lazy loading of big image data, was used to visualize
the images in 2D slicing mode, crop stacks in x, y, z, and t, bin images (3 x 3 x 1 in x, y, z),
perform chromatic shift correction between channels and convert .h5 files from the InVi
SPIM into an Imaris compatible multi-resolution file format (.ims) for further analysis [90].
The oncogenic cells (H2B-GFP channel) displayed heterogeneous morphologies as well as
varying intensity textures, making it difficult to segment them using conventional thresh-
olding approaches. We thus used a trainable segmentation approach to convert the raw
intensity values into pixel probability maps, using the Fiji plugin called CATS [91]. Using
the H2B-GFP channel images as input, we trained three pixel classes: background, nucleus
center and nucleus boundary. For training we drew about 20(background), 120(nucleus
center), 100(nucleus boundary) labels distributed across the different time-frames of the
movie. After feature computation and training of a Random Forest classifier the whole
dataset was processed on EMBL’s high performance computer cluster. The segmentation
of one data set -typically 100 timepoints- is distributed across few hundred jobs, each
job using 32 GB RAM, 16 cores, and running for about 30 minutes. The nucleus center
probability maps were then exported from CATS and added as an additional channel to
the converted intensity data.
The data were then loaded into Imaris [89] for 3D visualization and further processing.
Using the Imaris’ Surfaces function, we segmented the nucleus center probability maps
into objects. To do so, probability maps were manually thresholded, using a surface
smoothening parameter of 0.3 µm; the minimum quality parameter for seed points was
set to 0.1, and object splitting was applied for objects larger than 5.5 µm. Objects
with volumes less than 20 µm3 were excluded. Next, all objects were tracked over time
using Imaris’ Lineage tracking algorithm with a maximum distance between objects in
subsequent time-points limited to 10 µm and a maximum gap size between identification
of the object in a particular track limited to 10 time points. Most of the errors in the
object segmentation were false merges, where two cells were segmented as one (Figure
2.11. This kind of error is frequently not sustained in the previous or following time-
points and the maximum gap size parameter of the tracking algorithm thus frequently
provides correct tracks nonetheless. The resulting lineage trees of proliferating tumour
cells within the organoid were corrected manually within Imaris, e.g., excluding apoptotic
cells and auto-fluorescent debris. Center of mass coordinates of each cell were measured
and exported from Imaris for subsequent feature analysis.
4.7.4 Computational feature analysis
Observations suggest that tumors in organoids originate from clusters of oncogene-expressing
cells produced by independent transduction events. To identify these clusters, we com-
puted the pairwise Euclidean distances between all oncogene-expressing cells in an organoid
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at the start of the experiment and applied hierarchical clustering with complete linkage.
Clusters were identified automatically by cutting the branches of the trees using the dy-
namic tree cut algorithm [92]. This defined a cluster as a group of oncogene-expressing
cells that are closer to each other than to other oncogene-expressing cells of the same
organoid. Note that a cluster can be composed of a single cell if this cell is comparatively
isolated from other transduced cells. For each cluster we identified the following features
as possibly linked to tumor formation:
(1) number of cells in the organoid
(2) cell density expressed as the ratio of number of cells to organoid surface area computed
by assuming the organoid is a sphere with diameter equal to the distance between the two
most distant cells
(3) number of oncogene-expressing cells in the organoid
(4) number of cells (including both oncogene-expressing and normal cells) in the cluster
volume defined as the sphere centered at the center of mass of the cluster with diameter
equal to the distance between the two farthest oncogene-expressing cells of the cluster
(5) number of oncogene-expressing cells in the cluster
(6) average pairwise distance between all cells in the cluster volume
(7) average pairwise distance between oncogene-expressing cells in the cluster
(8) fraction of oncogene-expressing cells in the cluster volume
(9) number of contacts between oncogene-expressing cells in the cluster. Two cells are
presumed in contact if they are less than the average cell diameter + 2 standard deviation
apart.
Oncogene-expressing cells were tracked over time and a cluster was associated with a
tumor outcome if any of its cells lead to tumor formation. To identify which features were
linked to this outcome, we took an information-theoretic approach to model selection.
We fitted a logistic regression model for all possible linear combinations of features and
selected the best model based on the Akaike information criterion (with correction for
small sample sizes) [93]. This model included only three features: number of oncogene-
expressing cells in the cluster, number of oncogene-expressing cells in the organoid and
number of cells in the cluster of which only the first (number of oncogene-expressing cells
in the cluster) contributed significantly to tumor formation with an odds ratio of 9.1.
Computing relative variable importance across all models also indicated that the number
of oncogene-expressing cells in a cluster is the most important feature.
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4.8 RNA Seq data analysis
4.8.1 RNA extraction
For RNA sequencing analysis of organoids in 3D culture, 2 gels of 100µl volumes were
pooled during harvest. At the predetermined timepoint, media from the wells were re-
moved and gels were digested using 900 µl of mirVana lysis buffer, and subsequently
extracted using mirVana miRNA Isolation Kit (Ambion, Cat. # AM1560). RNA quality
and concentration was assessed using the Bioanalyzer (Agilent 2100, Cat. # G2939BA)
at the Genomics Core facility, EMBL, Heidelberg. RNA was sequenced in the Genomics
Core on Illumina NextSeq 500 platform, using NGS HiSeq protocol – 75bp read length,
30x coverage.
4.8.2 RNA Seq data analysis
After assessing the quality of the raw RNA sequencing reads by FastQC version 0.11.3
[201], adapter trimming using cutadapt version 1.9.1 [202] with default options providing
the standard Illumina TrueSeq Index adapters was done. FaQCs version 1.34 [203] was
used for subsequent quality trimming and filtering, applying following parameters: -q 20
-min L 25 -n 5 -discard 1. This resulted in 34,1 to 52 million total reads per sample.
Reads were further aligned to the reference genome (mouse-GRCm38.p4) using Tophat2
version 2.0.10 [204] with the following parameter: -G -T -x 20 -M - -microexon-search -
- nocoverage-search - -no-novel-juncs-mate-std-dev 100-r 50 -min-segment-intron 20 -I 30
-a6. For differential expression analysis, only reads with unique mappings were consid-
ered. The count HTSeq python library version 0.6.1.pl. script [205] with default options
was used to obtain gene level count tables. All reads mapped in total to 19500-20800
genes and the statistical analysis was done with Bioconductor package DESeq2 version
1.12.4 [206]. Normalization was done based on size-factor to control for batch effects and
inter-sample variability. Package defaults were used for dispersion estimation and differ-
ential expression analysis, which include multiple testing correction, independent filtering
and Cook’s cutoff [207] for outlier detection. For comparison of gene expression between
residual versus normal cells, DESeq2 raw p-values were used as input to fdrtool version
1.2.15 [208] to compute q-values. Genes with q-value0,05 were considered as significantly
differentially expressed. For comparison of gene expression between tumor versus normal
cells, Bonferroni correction was used for multiple testing correction and genes with padj
0,1 were considered as significantly differentially expressed. R V.3.3.1. (R Development
Core Team) was used for conducting biostatistical analyses. For performing dimensional-
ity reduction with Principal Component analysis (PCA) and hierarchical clustering rlog
DESeq2 transformed transcript counts were utilized. For the calculation of the ellipses on
the PCA plots the “sat ellipse” function from the R package ggplot2 was used.
115
Materials and Methods
4.8.3 Clustering and Correlation analysis
Clustering analysis using GPClust [209], yielded over 2000 genes into 75 clusters with
FDR (false discovery rate) of 1%. Individual analysis of gene trajectories in interesting-
trajectory clusters was used to classify interesting trajectories into 5 broad manually cu-
rated clusters:
I. Sustained targets – upregulated consistently during regression up to MRD state
II. Early responders – unregulated early during regression before apoptosis decisions are
made (up to 8 hours after de-induction)
III. Intermediate responders – unregulated after apoptosis decisions are made to poten-
tially salvage residual cells/aid in tissue rearrangement to increase survival (12-24 hours
after de-induction)
IV. Late targets – unregulated during re-polarization of epithelial cells into residual rim
(36 hours after de-induction onwards)
V. Shoulder trajectories – Upregulated in tumors and continued sustained expression dur-
ing regression (at least up to 34 hours after de-induction).
Correlation analysis performed by Katharina Zirngibl was used to enrich the afore-
mentioned clusters from the whole dataset of differentially regulated genes based on gene
expression trajectories.
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4.8.4 Gene enrichment analysis
Gene enrichment analysis was performed on the 1796 identified targets from the 5 man-
ually curated clusters using Cytoscape software by Matt Rogon. Analysis of individual
and multi-cluster gene ontology analysis yielded a wealth of interesting pathways and gene
families that were differentially regulated. The following Gene Ontology terms were man-
ually picked for further network mapping and druggable target analysis on Cytoscape:
I. GO:0002819 Regulation of adaptive immune response
II. GO:0098742 Cell-cell adhesion via plasma-membrane adhesion molecules
III. GO:0002009 Morphogenesis of an epithelium
IV. GO:0001213 Formation of the cornified envelope
V. GO:0031663 Lipopolysaccharide-mediated signaling pathway
VI. GO:0017017 MAP kinase tyrosine/serine/threonine phosphatase activity
VII. GO:0000097 Downregulation of ERBB4 signaling
VIII. GO:0000618 Oxidative Stress Induced Senescence
IX. GO:0008593 Regulation of Notch signaling pathway
X. GO:0000571 FAS pathway and Stress induction of HSP regulation
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4.9 Microarray data analysis
4.9.1 RNA extraction
TetO-MYC/ TetO-Neu/ MMTV-rtTA adult female mice induced to have tumors were
organ-harvested during regression phase after removal of doxycycline from the animal
diet. During harvest 20-30 mg tissue pieces were snap frozen in liquid nitrogen for RNA
extraction. The snap frozen tissue pieces were ground in a mortar and pestel (maintained
at -50◦C by placing it in a trough full of dry ice). The frozen tissue powder was then
transferred to an Eppendorf tube with 900µl of mirVana lysis buffer. Total RNA was
subsequently extracted using mirVana miRNA Isolation Kit (Ambion, Cat. # AM1560).
RNA quality and concentration were assessed using the Bioanalyzer (Agilent 2100, Cat.
# G2939BA) at the Genomics Core facility, EMBL, Heidelberg. RNA extracted from
the mammary gland tissues at hallmark time points during regression were were run on
Affymetrix MoGene-2 microarray chips.
4.9.2 Microarray data analysis
Microarray data files was analysed using the Transcriptome Analysis Console (TAC) 4.0
software. Principal Component Analysis (PCA) plotting and differentially regulated path-
ways compared to the control samples were curated manually. Manual overlay of gene en-
richment analysis for both in vivo and datasets yielded the following interesting subgroup
of pathways:
(a) Focal Adhesion PI3K- AKT-mTor Sinalling Pathway
(b) MAPK Signalling (specifically: c-Jun Kinase/Stress-activated Pathway)
(c) TNF-alpha and NfKb signalling pathway
(d) Tgf-Beta Signalling pathway
(e) DNA damage response (ATM dependent)
(f) Apoptosis pathways.
Key molecular players from these pathways were selected for validation, including c-Jun,
BCl-6, CCL5 and c-Rel.
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Organoid Movie Code Tumor outcome
Organoid-1 0308S1 Yes
Organoid-2 0308S2 Yes
Organoid-3 0308S3 No
Organoid-4 0308S4 Yes
Organoid-5 0308S8 Yes
Organoid-6 2607S0 Yes
Organoid-7 2607S2 No
Organoid-8 2607S6 No
Organoid-9 2607S11 Yes
Organoid-10 3107S0 No
Organoid-11 3107S1 No
Organoid-12 3107S2 Yes
Organoid-13 3107S3 No
Organoid-14 31074 No
Organoid-15 3107S5 No
Organoid-16 2111S0 Yes
Organoid-17 2111S2 No
Organoid-18 2111S4 Yes
Organoid-19 2111S6 Yes
Organoid-20 2111S8 Yes
Table 5.1: List of transduced organoids analyzed for feature analysis.
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Figure 5.1: Hierarchical clustering of transduced cells in bi-transgenic organoids undergo-
ing stochastic tumourigenesis. Organoids are name coded according to Table 5.1.
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Figure 5.2: Hierarchical clustering of transduced cells in bi-transgenic organoids undergo-
ing stochastic tumourigenesis. Organoids are name coded according to Table 5.1.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
%Genes / Term
establishment of skin barrier
Formation of the cornified envelope
positive regulation of Notch signaling pathway
regulation of bone remodeling
regulation of homotypic cell-cell adhesion
regulation of coenzyme metabolic process
nucleoside diphosphate metabolic process
negative regulation of purine nucleotide metabolic process
6
14
3
4
3
5
8
3
**
**
.
Figure 5.3: Gene Ontology Enrichment analysis of genes with ’Target’ trajectories.
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Figure 5.4: Gene Ontology Enrichment analysis of genes with ’Early Responder’ trajecto-
ries.
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Figure 5.5: Gene Ontology Enrichment analysis of genes with ’Intermediate Responder’
trajectories.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
%Genes / Term
regulation of immunoglobulin mediated immune response
intracellular transport of virus
Renin secretion
inactivation of MAPK activity
MAP kinase tyrosine/serine/threonine phosphatase activity
Downregulation of ERBB4 signaling
Activated NOTCH1 Transmits Signal to the Nucleus
Glycogen synthesis
Josephin domain DUBs
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
Negative regulators of RIG-I/MDA5 signaling
IRAK2 mediated activation of TAK1 complex
TRAF6 mediated induction of TAK1 complex
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
IRAK2 mediated activation of TAK1 complex upon TLR7...
5
3
3
4
4
5
5
5
5
5
5
5
5
5
5
.
*
**
Figure 5.6: Gene Ontology Enrichment analysis of genes with ’Late Responder’ trajecto-
ries.
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Figure 5.7: Gene Ontology Enrichment analysis of genes with ’Shoulder’ trajectories.
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Figure 5.8: Gene network for the ’Cell-cell adhesion via plasma-membrane adhesion
molecules’ GO Term. Yellow diamonds represent all genes in the network. Blue cir-
cles represent the first neighbours of all genes based on protein-protein interactions. Pink
diamonds represent the deferentially regulated genes in the network during the process of
tumor regression in the organoid cultures. Dark blue borders on genes indicate that the
gene is druggable with known inhibitors.
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Figure 5.9: Gene network for the ’FAS pathway and Stress induction of HSP regulation’
GO Term. Yellow diamonds represent all genes in the network. Blue circles represent
the first neighbours of all genes based on protein-protein interactions. Pink diamonds
represent the deferentially regulated genes in the network during the process of tumor
regression in the organoid cultures. Dark blue borders on genes indicate that the gene is
druggable with known inhibitors.
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Figure 5.10: Gene network for the ’Formation of the cornified envelope’GO Term. Yellow
diamonds represent all genes in the network. Blue circles represent the first neighbours of
all genes based on protein-protein interactions. Pink diamonds represent the deferentially
regulated genes in the network during the process of tumor regression in the organoid
cultures. Dark blue borders on genes indicate that the gene is druggable with known
inhibitors.
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Figure 5.11: Gene network for the ’MAP kinase tyrosine/serine/threonine phosphatase
activity’ GO Term. Yellow diamonds represent all genes in the network. Blue circles
represent the first neighbours of all genes based on protein-protein interactions. Pink
diamonds represent the deferentially regulated genes in the network during the process of
tumor regression in the organoid cultures. Dark blue borders on genes indicate that the
gene is druggable with known inhibitors.
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Figure 5.12: Gene network for the ’Regulation of adaptive immune response’ GO Term.
Yellow diamonds represent all genes in the network. Blue circles represent the first neigh-
bours of all genes based on protein-protein interactions. Pink diamonds represent the
deferentially regulated genes in the network during the process of tumor regression in the
organoid cultures. Dark blue borders on genes indicate that the gene is druggable with
known inhibitors.
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Figure 5.13: Gene network for the ’Lipopolysaccharide-mediated signaling pathway’ GO
Term. Yellow diamonds represent all genes in the network. Blue circles represent the first
neighbours of all genes based on protein-protein interactions. Pink diamonds represent
the deferentially regulated genes in the network during the process of tumor regression
in the organoid cultures. Dark blue borders on genes indicate that the gene is druggable
with known inhibitors.
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Figure 5.14: Gene network for the ’Oxidative Stress Induced Senescence’GO Term. Yellow
diamonds represent all genes in the network. Blue circles represent the first neighbours of
all genes based on protein-protein interactions. Pink diamonds represent the deferentially
regulated genes in the network during the process of tumor regression in the organoid
cultures. Dark blue borders on genes indicate that the gene is druggable with known
inhibitors.
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Figure 5.15: Gene network for ’Downregulation of ERBB4 signaling’ GO Term. Yellow
diamonds represent all genes in the network. Blue circles represent the first neighbours of
all genes based on protein-protein interactions. Pink diamonds represent the deferentially
regulated genes in the network during the process of tumor regression in the organoid
cultures. Dark blue borders on genes indicate that the gene is druggable with known
inhibitors.
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Figure 5.16: Gene network for the ’Regulation of Notch signaling pathway’ GO Term.
Yellow diamonds represent all genes in the network. Blue circles represent the first neigh-
bours of all genes based on protein-protein interactions. Pink diamonds represent the
deferentially regulated genes in the network during the process of tumor regression in the
organoid cultures. Dark blue borders on genes indicate that the gene is druggable with
known inhibitors.
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Figure 5.17: Gene network for the ’Morphogenesis of an epithelium’ GO Term. Yellow
diamonds represent all genes in the network. Blue circles represent the first neighbours of
all genes based on protein-protein interactions. Pink diamonds represent the deferentially
regulated genes in the network during the process of tumor regression in the organoid
cultures. Dark blue borders on genes indicate that the gene is druggable with known
inhibitors.
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Figure 5.18: Cell Viability and Cell Death readouts from synthetic lethality testing of the
CXCR5 antagonist Maraviroc. Upper left graph shows the readout from the CellTiter-
Glo R© Luminescent Assay. Cell viability readouts for the 5 doses of Maraviroc tested and
normalized against the control are shown. Derived from this graph is the upper right
graph depicting the Cell Viability response curve. IC50 values for Maraviroc in the Cell
Viability response curve are 0.0287 mM for Never Induced and 0.0286 mM for Regressed
cultures. Lower left graph shows the readout from the CellToxTM Green Fluorescence
Assay. Cell death readouts for the 5 doses of Maraviroc tested and normalized against
the control are shown. Derived from this graph is the lower right graph depicting the Cell
Death response curve. IC50 values for Maraviroc in the Cell Death response curve are 0.1
mM for Never Induced and 0.028 mM for Regressed cultures.
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Figure 5.19: Cell Viability and Cell Death readouts from synthetic lethality testing of
the IKK2 Inhibitor IV. Upper left graph shows the readout from the CellTiter-Glo R©
Luminescent Assay. Cell viability readouts for the 5 doses of IKK2 Inhibitor IV tested
and normalized against the control are shown. Derived from this graph is the upper right
graph depicting the Cell Viability response curve. IC50 values for IKK2 Inhibitor IV in the
Cell Viability response curve are 0.02 mM for Never Induced and 0.017 mM for Regressed
cultures. Lower left graph shows the readout from the CellToxTM Green Fluorescence
Assay. Cell death readouts for the 5 doses of IKK2 Inhibitor IV tested and normalized
against the control are shown. Derived from this graph is the lower right graph depicting
the Cell Death response curve. IC50 values for IKK2 Inhibitor IV in the Cell Death
response curve are 0.02 mM for Never Induced and 0.00073 mM for Regressed cultures.
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Figure 5.20: Cell Viability and Cell Death readouts from synthetic lethality testing of
the IKK2 Inhibitor VIII. Upper left graph shows the readout from the CellTiter-Glo R©
Luminescent Assay. Cell viability readouts for the 5 doses of IKK2 Inhibitor VIII tested
and normalized against the control are shown. Derived from this graph is the upper
right graph depicting the Cell Viability response curve. IC50 values for IKK2 Inhibitor
VIII in the Cell Viability response curve are 0.016 mM for Never Induced and 0.035 mM
for Regressed cultures. Lower left graph shows the readout from the CellToxTM Green
Fluorescence Assay. Cell death readouts for the 5 doses of IKK2 Inhibitor VIII tested
and normalized against the control are shown. Derived from this graph is the lower right
graph depicting the Cell Death response curve. IC50 values for IKK2 Inhibitor VIII in the
Cell Death response curve are 0.027 mM for Never Induced and 0.03055 mM for Regressed
cultures.
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Figure 5.21: Cell Viability and Cell Death readouts from synthetic lethality testing of
FX-1. Upper left graph shows the readout from the CellTiter-Glo R© Luminescent Assay.
Cell viability readouts for the 5 doses of FX-1 tested and normalized against the control
are shown. Derived from this graph is the upper right graph depicting the Cell Viability
response curve. IC50 values for FX-1 in the Cell Viability response curve are 0.009 mM for
Never Induced and 0.013 mM for Regressed cultures. Lower left graph shows the readout
from the CellToxTM Green Fluorescence Assay. Cell death readouts for the 5 doses of
FX-1 tested and normalized against the control are shown. Derived from this graph is the
lower right graph depicting the Cell Death response curve. IC50 values for FX-1 in the
Cell Death response curve are 0.0174 mM for Never Induced and 0.022 mM for Regressed
cultures.
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